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Abstract 
BACKGROUND: Soft tissue sarcomas (STS) are rare heterogeneous human malignant 
neoplasms, accounting for 1% of all human malignancies, arising mostly from various 
mesenchymal tissue. Heat shock proteins (HSPs) are involved in cell proteostasis, and their 
expression by cancer cells allows the cells to survive, invade and undergo metastasis.  
AIMS: The purpose of this thesis was to investigate the potential role of key HSPs (HSP27, 
HSP70 and HSP90) in fibroblastic/myofibroblastic tumours of the extremities.  
METHODS: Expression of HSP27, HSP70 and HSP90 were analysed using 
immunohistochemistry on tissue sections from 35 cases of fibroblastic/myofibroblastic 
sarcomas and 8 cases of non-metastasising fibroblastic tumours. The expression of each protein 
was evaluated and its relationship with clinicopathological parameters examined.  
RESULTS: HSP27 and HSP70 were expressed in all fibroblastic/myofibroblastic tumours, 
but only the expression of HSP70 was significantly higher in sarcomas compared to non-
metastasising counterparts (P < 0.05). Also, there was a significant relationship between 
HSP70 expression and the grade of sarcomas (P < 0.05). However, no significant association 
found between HSP27 and HSP90 expression and clinicopathological features of sarcomas.   
CONCLUSIONS: The findings of this study indicate that HSP70, and to a lesser extent 
HSP27, might have a role in sarcoma behaviour (as defined by the surrogates of tumour type 
and grade) and may provide prognostic information for clinicians in the future. Further studies 
are warranted to gain more insight into the role of these HSPs in the tumorigenesis of soft tissue 
sarcomas to determine whether they are possible markers of prognosis. 
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1 Introduction and literature review 
 
1.1 Soft tissue sarcoma (STS) 
Soft-tissue sarcomas (STS) are a heterogeneous group of rare malignant tumours which arise 
from mesenchymal tissue in essentially every tissue of the body. They can differentiate along 
many tissue lineages, such as adipose, fibrous, cartilage, muscle or bone. Their natural 
behaviour is different from that of epithelial tumours (1). The biology of sarcomagenesis is not 
precisely understood, but models of stepwise progression to malignancy or in situ precursor 
lesions are not founded in the manner of many of the epithelial neoplasms. In opposition to 
epithelial tumours, sarcomas often do not arise from their corresponding mature adult tissue, 
and the progenitor cell remains unclear (2). Furthermore, soft tissue tumour behaviour is 
classified as benign, intermediate (locally aggressive), intermediate (rarely metastasizing), and 
malignant (3).  
1.1.1 Incidence and Epidemiology 
STSs account for approximately 1% of all adult malignancies, equating to approximately 
1,500-2,000 cases a year in the UK (4). They can occur in any age group, however, the 
incidence of soft-tissue sarcomas rises significantly with age, with more than 65% of cases 
affecting patients aged 50 and above (5). A STS can occur in almost any site of the body, 
making it distinct amongst other human growths. The most common site of sarcoma is in the 
extremities (66%), with approximately two thirds of these occurring in the lower limbs (6). In 
2010, there were 3298 newly diagnosed cases of soft tissue sarcoma in the UK, of which 51% 
 
- 17 - 
were in males and 49%were in females. Although the yearly incidence of soft tissue sarcoma 
is regularly higher in males than females, this difference is not statistically significant (4). 
1.1.2 Aetiology and Risk factors 
The aetiology of most soft tissue sarcoma remains unknown; however, it has been associated 
with genetic diseases, viral infections, and environmental factors (7). Furthermore, inherited 
diseases have been found to be related to sarcoma development. For example, Lі-Fraumeni 
syndrome caused by germline mutations in the p53 tumour suppressor gene leads to sarcoma 
formation and neurofibromatosis Type 1 can also result in the development of peripheral nerve 
sheath tumours (8). Also, it is known that exposure to radiotherapy, as a treatment for other 
cancers, has an association with the development of STS. The most common sub-types of 
sarcoma in patients receiving radiotherapy are extra-skeletal osteogenic sarcoma (21%) and 
undifferentiated pleomorphic sarcoma (16%) (9). 
1.1.3 WHO classification 
As part of the International Classification of Diseases (ICD), the World Health Organisation 
(WHO) publishes classification systems for all types of cancer. The ‘WHO Classification of 
Tumours of Soft Tissue and Bone’, a sub classification of ICD covers sarcomas. This was 
revised in 2013 and published in a 4th Edition and provides a universal nomenclature which 
helps to ensure comparability of international clinical trials and translational research (10). 
Although the WHO system depends on morphologic appearance to classify STS, the new 
system of classification includes much more detailed cytogenetic and molecular data in keeping 
with the exponentially increasing knowledge on the genetics of tumours. One important change 
is the removal of the term ‘malignant fibrous histiocytoma’ (MFH). This was previously one 
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of the most common diagnoses within soft-tissue sarcomas, but advances in molecular 
diagnosis have shown that these tumours should be classified with other more specific types of 
sarcoma as ‘myxofibrosarcoma’ (10). However, this leaves a small number of tumours that do 
not come under the diagnostic criteria of other specific types. Hence, the new WHO 
classification of soft tissue sarcomas has more than 50 histologic subtypes. A simplified 
classification of STSs by cell type differentiation is presented in Table 1.1. 
Table 1.1 The WHO Classification of STSs.  
WHO Classification of Soft Tissue Tumours Most Common Sarcoma Subtype 
Adipocytic tumours Liposarcoma 
Fibroblastic/myofibroblastic tumours Myxofibrosarcoma, Low grade Fibromyxoid sarcoma, 
Myxoinflammatory fibroblastic sarcoma, 
Myofibroblastic sarcoma 
Smooth-muscle tumours Leiomyosarcoma 
 





Peripheral nerve tumours Malignant Peripheral Nerve Sheath Tumour (MPNST) 
 
Tumours of uncertain origin Synovial sarcoma, Epithelioid sarcoma, 
Extra-skeletal Ewing sarcoma, Clear cell sarcoma 
Adapted from WHO Classification of Tumours of Soft Tissue and Bone. 2013 (3) 
 
The five most common STSs in adults are undifferentiated pleomorphic sarcoma (28%), 
liposarcoma (15%), leiomyosarcoma (12%), synovial sarcoma (10%), and malignant 
peripheral nerve sheath tumours (MPNST) (6%), whereas the residual 45 histological STS sub-
types represent the remaining 29% (11).  
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1.1.4 Diagnosis of STS 
Any patient with a suspected STS should have a triple assessment with clinical history, imaging 
and biopsy. In the UK, The National Institute for Health and Care Excellence (NICE) provides 
comprehensive guidelines for the management of soft tissue sarcoma. To achieve a successful 
diagnosis of STS, a collaboration between the specialist radiologists, surgeons, oncologists and 
pathologists is vital; prompt referral to specialist centres is designed to facilitate early and 
consistent diagnosis (12). 
1.1.4.1 Clinical presentation and patient examination 
Due to the various sites of origin of STS, it is difficult to clearly define the clinical features of 
the disease. Nonetheless, the most common presentation of a STS is as a painless mass 
increasing in size. The clinical history should inquire about a personal or family history of 
cancer or pre-malignant/inherited conditions such as neurofibromatosis, Li-Fraumeni 
Syndrome or Multiple Hereditary Exostoses, as well as other lesions. Clinical examination is 
the standard examination of any lump plus an assessment of the neurovascular status distally 
and palpation of both local and systemic lymph nodes. Approximately one third of sarcomas 
are superficial to the fascia, the remainder are deep. Usually, local symptoms develop late. A 
large tumour may cause compression of neural and vascular structures, resulting in radicular 
pain, venous stasis and lymphedema. In the advanced stage, the tumour may infiltrate the 
overlying skin, causing ulceration or necrosis (12, 13). 
1.1.4.2 Imaging 
Imaging investigations such as X-rays, ultrasound, CT scan, and magnetic resonance imaging 
(MRI) are also used to determine the anatomical location of the tumour, its size and infiltration 
into the surrounding tissues. A standard X-ray may be used to identify any connection with, or 
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erosion into, bone or calcification within the mass and ultrasound is often utilised in the primary 
care setting. NICE recommends urgent ultrasonography, within two weeks in adults and within 
two days for children and young people, for all unexplained lumps increasing in size (13). 
When the mass is smaller than 5 cm and superficial, ultrasound is appropriate, but when larger 
than 5 cm or deep, sarcoma centre referral and MRI scanning is mandatory. A MRI is preferred 
to CT for further information regarding size, location and extent of the tumour to help plan the 
biopsy and surgical intervention. For staging, a chest radiograph and CT thorax (plus or minus 
abdomen and pelvis) are required. An isotope bone scan has a limited role, whereas whole body 
MRI is an established technique in STS staging of myxoid liposarcoma because of their 
propensity for unusual metastases (14). 
1.1.4.3 Biopsy 
Despite advanced imaging techniques, there is only one reliable method of establishing 
whether a soft tissue tumour is benign or malignant, and that is by performing a biopsy on the 
tumour. Hence, a biopsy is the required initial procedure for all soft tissue lumps or masses that 
persist or increase in size. Numerous biopsy techniques are available, including: open 
incisional biopsy (where a portion of the tumour is removed), open excisional biopsy (where 
the entire tumour is removed), core needle biopsy (CNB), fine-needle aspiration (FNA), and 
core biopsy. Biopsy should be performed within the sarcoma diagnostic or treatment centre 
(12). 
FNA is a convenient technique to perform, being a relatively short procedure that may be 
conducted under local anaesthetic in an outpatient clinic. However, it can be difficult to make 
an accurate primary diagnosis with FNA alone. It should be used in centres in which 
cytopathologists have experience in both the FNA technique and the interpretation of the 
results. The diagnostic accuracy of FNA, based on results of patients with primary tumours, 
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ranges from 60% to 96% (15). In other instances, FNA provides only a cytological sample with 
scant tissue, consequently, accurate typing and grading are not usually possible.  
Core needle biopsy (CNB), usually under ultrasound guidance, is the method of choice, as it is 
a safe, accurate, and economical procedure for diagnosing STS. It provides an adequate sample 
for use in several diagnostic analyses, such as cytogenetic analysis and electron microscopy. 
Frequently, diagnosis is made on CNB material, and tumour subtype and grade can be 
determined in about 80% of core biopsies (16). Additionally, it is usually performed under CT 
or, less commonly, ultrasound guidance. CNB has been shown to be effective in the diagnosis, 
and sub-typing or grading of STS and, moreover, has lower morbidity. It also has a sensitivity 
of 82–100% and a specificity of 91–100% in STS, with complication rates of 0–1.1% (17).  
This is a reliable diagnostic method for obtaining an adequate and representative sample of 
tissue for diagnosis. It is usually performed when a diagnosis has not been possible from fine-
needle aspiration or core needle biopsy specimens. It is performed in a designated treatment 
centre, preferably by the same surgeon who will carry out the surgery, and hence, the procedure 
requires careful surgical planning. The direction of the incision should be orientated 
longitudinally along the extremity such that the resulting biopsy tract is easily excised at the 
time of the definitive tumour resection procedure (18).  
Excision biopsy is sometimes straightforward and easily accessible at the outset, but this is 
usually reserved for tumours with certain features outside the sarcoma treatment centre, such 
as when the lump is superficial, well defined and < 3 cm in diameter (19). However, the benefits 
of excisional biopsy rarely exceed those of other biopsy techniques, and these procedures may 
also cause post-operative complications so ultimately, it would be best to perform a diagnostic 
biopsy first and delay the final surgical treatment (11).  
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1.1.5 Histology 
Histological diagnosis of soft tissue tumours is known as being one of the most challenging 
areas in histopathology. For example, there is significant morphological overlap between soft 
tissue neoplasms and reactive lesions. Some aggressive sarcomas appear histologically bland 
while reactive conditions such as nodular fasciitis show potentially worrying characters 
including high cellularity and mitotic activity. Furthermore, A broad range of different soft 
tissue tumours have spindle cell morphology, and ancillary stains may be required to show 
specific differentiation features. Since identifying a histopathologic type of sarcoma is often 
difficult, some ancillary methods, such as immunohistochemistry and genetic analysis, are 
helpful in supporting the morphologic diagnosis.  
1.1.5.1 Immunohistochemistry (IHC) 
The diagnostic IHC technique was introduced in the early 1980s and it can localise molecules 
in tissues by observing histological staining due to the binding of specific antibodies (20). It is 
now a regular tool for evaluating the diagnosis and prognosis of tumours due to its relatively 
low cost, simplistic technique and the availability of a large number of increasingly sensitive 
and specific antibodies. In addition, IHC is important in the diagnosis of STSs because of their 
variety, with several lines of differentiation, and the common difficulty of diagnosis with 
numerous pseudosarcomatous benign lesions and non-mesenchymal malignant tumours (20). 
The impact of IHC in pathology may be explained by three major advances, the availability of 
appropriate antibodies for routine formalin-fixed tissue, improvements in antigen retrieval 
methods (particularly heat-induced epitope retrieval which provides consistent and reliable 
results), and the availability of sensitive detection systems (21). However, IHC also has its 
limitations, since no IHC marker is wholly specific for any tumour and positive findings should 
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be taken in the context of the total antibody panel and the tumour morphology. For example, 
CD99, originally thought to be specific for Ewing sarcoma, is expressed to varying degrees in 
several tumours, including those in the Ewing sarcoma differential diagnosis, such as poorly 
differentiated synovial sarcoma (22). Also, CD117 (cKIT), positive in more than 95% of 
gastrointestinal stromal tumours (GISTs), is variably expressed in other tumours, such as 
angiosarcoma, Ewing sarcoma, synovial sarcoma, leiomyosarcoma, and MFH (23). In 
addition, sometimes the inappropriate antibody panels are selected because of incorrect light 
microscopic analysis, resulting in IHC results which are internally consistent, but completely 
inaccurate. Moreover, the continuing delineation of new entities and production of new 
antibodies will lead to the expansion of panels required for differential diagnosis, particularly 
when there are critical therapeutic options. The most important markers used in the differential 
diagnosis of STS and their diagnostic targets are listed in Table 1.2.  
Table 1.2 Markers used in the differential diagnosis of STS.  
IHC Markers Diagnosis 





Angiosarcoma, Kaposi sarcoma 
Kaposi sarcoma, many vascular fibroblastic 







Smooth and skeletal tumours, myofibroblastic 
Smooth and skeletal tumours 
Smooth muscle, myofibroblasts, myoepithelial, synovial sarcoma 







Histiocytes, myelomonocytic cells 
Histiocytes, macrophage, schwanoma 
Histocytes 
 









Melanocytic, schwannian, chondroid 
Synovial and epithelioid sarcoma 
Mesenchymal tumours, many poorly differentiated carcinoma 
Osteosarcoma, osteoid material 
Ewing sarcoma 
Epithelial tumours in general, Ewing sarcoma 
Adapted from Miettinen, 2003 (24) 
 
Aggressive tumour phenotypes are characterised by vascular invasion, metastasis and local 
recurrence; however, this is more about research than current diagnostic work. For example, 
the factor VIII can be used to measure vessel density, Ki-67 is a marker of proliferation, and 
the p53, p27 and Bcl2 proteins are all related to the regulation of the cell cycle, hence, linked 
to apoptosis. Furthermore, the expression of CD44 and ezrin are associated with cell adhesion, 
and related to cell migration and metastasis (1, 24). No immunohistochemical marker is 
completely specific for any tumour and positive findings should be considered against the 
background of the total antibody panel as well as the tumour morphology (20).  
1.1.5.2 Genetic Analysis 
Occasionally, a diagnosis is not possible from morphologic features and IHC, therefore, the 
detection of sarcoma with specific genetic alterations, such as chromosomal translocation and 
complex karyotypes, represents an additional diagnostic and prognostics tool in STS (25). STS 
with recurrent chromosomal translocations can be classified into sub-types depending on the 
presence of fusion gene transcripts, for example, TLS-CHOP in myxoid or round cell 
liposarcoma, SYT-SSX (SYT-SSX1 or SYT-SSX2) in synovial sarcoma, EWS-ATF1 in clear 
cell sarcoma, and PAX-FKHR (PAX3-FKHR or PAX7-FKHR) in alveolar 
rhabdomyosarcoma. The fusion genes resulting from chromosomal translocations could be of 
clinical importance for diagnostic and prognostic information (1).  
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Kawai et al. suggested that the type of SYT-SSX fusion gene may be prognostic for survival 
in patients with synovial sarcoma. Another study found that 46% of synovial sarcomas have 
SYT-SSX1 and 36% have SYT-SSX2. The five-year survival for localised synovial sarcoma 
with the SYT-SSX2 was 48% as compared to 24% for patients with SYT-SSX1. Therefore, 
the type of SYT-SSX fusion gene appears to positively influence subsequent clinical behaviour 
in synovial sarcoma (26).  
There are several techniques that can be used for cytogenetic analysis, but the main techniques 
are fluorescence in–situ hybridisation (FISH), reverse-transcriptase polymerase chain reaction 
(RT-PCR), and the more recent, gene expression profiling (1). It has been suggested that the 
molecular heterogeneity of the fusion transcript is useful in predicting the prognosis in 
particular sub-types of sarcoma. For example, fusion transcript type 1 EWS-FLI1 has been 
demonstrated to indicate better survival in patients with Ewing sarcoma than other fusion gene 
transcripts (27). Also, in alveolar rhabdomyosarcoma, the presence of PAX7-FOXO1A has 
been associated with a favourable prognosis, compared with the more common PAX3-
FOXO1A (28). In patients with synovial sarcoma, a less clear impact has been noted among 
the fusion gene transcripts SYT-SSX1 and SYT-SSX2 (1). 
In summary, genetic analysis appears promising, it involves highly complex techniques and 
has the potential to be useful for the differential diagnosis of sarcoma and the prediction of 
tumour behaviour. Additionally, the technical limitations associated with genetic analysis 
suggested that molecular evaluation be considered as an ancillary technique only. Genetic 
analysis findings should only be interpreted in the context of the morphologic features of a 
sarcoma (25, 29).  
Genetic markers represent an increasingly important field in STS diagnosis and prognosis. In 
general, the oncogenes, which can induce malignant transformation and cell proliferation, have 
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been implicated in the development of STS. In the majority of cases, oncogene activation 
results from chromosomal rearrangements or gene amplifications. Changes in the 
microenvironment of the gene, for example, following epigenetic modifications, must also be 
considered. Example of oncogenes linked to STS are the C-KIT and PDGFRA mutations in 
GIST, and the fusion oncogene, such as SS18-SSX, in 90% of synovial sarcoma (27). In 
contrast, tumour suppressor genes (TSG) play a critical role in cell growth and direct the cell 
programme toward programmed cell death or apoptosis. Unlike oncogene activation, the loss 
or change in the TSG function commonly results from deletions or discrete mutations. Two 
major TSGs that are relevant to STS are the retinoblastoma gene (RBI) and the TP53 gene 
(tumour protein p53). Approximately 30–60% of STSs have been reported to harbour 
aberrations of the TP53 gene, including a sub-set of patients with germ-line mutations i.e. the 
Li-Fraumeni syndrome (30).  
1.1.6 Prognostic factors 
The overall STS prognosis in terms of survival is 50% for high-grade sarcoma and 90% for 
low-grade sarcoma (31). Five prognostic factors determine the outcome of STS, depending on 
advanced patient age, presence of metastases at presentation, tumour size, grade and depth. Of 
these, histological grade has been shown to be the most critical factor (32). These prognostic 
factors appear to have slightly different importance in different studies and in aspects of STS 
prognosis (local recurrence rate, distant metastasis, and tumour-related death). In most studies, 
poor prognostic factors for local recurrence were microscopically positive margins, tumour 
size and, in some studies, patient age over 50 years. Tumour size and grade are the major 
determinants of death from tumours (33, 34). 
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1.1.6.1 Grading of STS 
Currently, the most important prognostic factor and the best indicator for accurate STS 
diagnosis is histological grade, and to help in this several grading systems have been developed. 
In the UK and Europe, the Fédération Nationale des Centres de Lutte Contre le Cancer 
(FNCLCC) grading system is commonly adopted, which defines three grades (32). This system 
is based on three pathological parameters, degree of tumour differentiation compared with 
normal tissue, mitotic count, and amount of tumour necrosis, as shown in Table 1.4. In addition, 
the value of the malignancy grade as the prognostic variable for STS has been reported by 
many groups (35). These classical parameters have been proven to have value as prognostic 
markers for decades. As shown by Fletcher et al., the mitotic index, the extent of tumour 
necrosis, and tumour size appear to be the most reliable predictors (8, 10).  




Score 1: Sarcomas closely resembling normal adult mesenchymal tissue (e.g., low 
grade leiomyosarcoma) 
Score 2: Sarcomas for which histological typing is certain (e.g., myxoid 
liposarcoma) 
Score 3: Embryonal and undifferentiated sarcomas, sarcomas of doubtful type 





Score 1: 0–9 mitoses per 10 HPF* 
Score 2: 10–19 mitoses per 10 HPF 





Score 0: no necrosis 
Score 1: <50% tumour necrosis 
Score 2: ≥50% tumour necrosis 
 
Histological Grade   
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 Grade 1: total score 2, 3 
Grade 2: total score 4, 5 
Grade 3: total score 6, 7, and 8 
 
Adapted from Coindre et al. 2006 (36). PNET – primitive neuroectodermal tumour. * high power field (HPF) 
measuring 0.1734 mm. 
 
To enhance the reproducibility and reliability of the system, the parameters are defined as 
exactly as possible to help to predict a chance of survival and distant metastatic rates of the 
patients with the tumours grade I–III. Nonetheless, many other grading systems are in use and 
are usually based on similar histological parameters, including the NCI (National Cancer 
Institute) three-grade system preferred in the USA. The Trojani/FNCLCC has confirmed slight 
superiority over NCI grading (37), and has been used to give the most complete survival data 
for STS to date. This is presented in Table 1.4.  
 
Table 1.4 Survival rates in STS according to the Trojani/FNCLCC grading system. 
Grade 5-year survival 10-year survival 
I 90% 85% 
II 70% 65% 
III 45% 30% 
Adapted from Kotilingam et al. 2006 (38). 
 
1.1.6.2 Tumour size and site 
The tumour size is of great importance in the prognosis. In this respect, STSs are divided into 
two groups according to whether they include T1 lesions, which are 5 cm or smaller, and T2 
lesions, which are larger than 5 cm, since the 5-cm criterion has widespread acceptance as a 
poor prognostic variable. Prognosis is particularly poor for tumours larger than 10 cm at 
presentation due to a high rate of metastatic recurrence (39). In addition, some authors have 
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suggested that the further stratification of tumours larger than 5 cm would give more accurate 
prognostic information. A study of 316 patients who were divided on the basis of tumour size 
into four groups, demonstrated that the prognosis of each group differed substantially, with 
tumour sizes of less than 5 cm, 5 to less than 10 cm, 10 to 15 cm, and greater than 15 cm, the 
five-year survival rates were found to be 84%, 70%, 50%, and 33% (40). Additionally, a 
relationship was found between the location of the tumour and its size. Those STSs in the distal 
extremities are generally both superficial and small at the time of diagnosis and have a better 
prognosis than those found intra-abdominally, which often reach large proportions before they 
can be diagnosed (19).  
1.1.6.3 Staging 
The most commonly adopted staging system for soft-tissue sarcoma is provided by the 
American Joint Committee on Cancer (AJCC) (Table 1.5). This AJCC system uses the four 
criteria of tumour size, nodal status, grade, and metastasis (TNGM) to designate one of four 
disease stages (41).  
Table 1.5 The American Joint Committee on Cancer Staging System, 7th edition. 
Tumour Size (T) 
T1 Primary tumour < 5cm (T1a –  superficial; T1b –  deep) 
T1 Primary tumour > 5cm (T2a –  superficial; T2b –  deep) 
 
Lymph Nodes (N) 
N0 No regional lymph nodes 
N1 Regional lymph nodes involved 
 
Metastases (M) 
M0 No metastases 
M1 Distant metastases 
 
Histological Grade (G) 
G1 Well differentiated 
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G2 Moderately differentiated 
G3 Poorly differentiated 
G3 Poorly differentiated or undifferentiated 
 
American Joint Committee on Cancer (AJCC) staging 
 
 STAGE 1: 
1A = low grade, small, superficial or deep (T1a-b, N0, M0, G1-2) 
1B = low grade, large, superficial (T2a-b, N0, M0, G1-2) 
 STAGE II: 
IIA = low grade, large, deep (T2b, N0, M0, G1-2) 
IIB = high grade, small, superficial or deep (T1a-b, N0, M0, G3-4) 
IIC = high grade, large, superficial (T2a, N0, M0, G3-4) 
 STAGE III: 
High grade, large, deep (T2B, N0, M0, G3-4) 
 STAGE IV: 
Any metastasis (Any T, N1 or M1, Any (G) 
 
Adapted from Edge et al., 2010 (41) 
 
Overall, tumour grade and size are the most important determinants of prognosis, with 
approximately two-thirds of all sarcomas being high-grade. Another study claims that the 
prognostic risk for metastatic disease is mostly dependent on the histopathologic grade in the 
first two or three years, but after that, the size of the tumour becomes at least as significant as 
grade (42). 
1.1.7 Treatment 
In the UK, soft tissue sarcomas are managed in a specialised sarcoma centre by 
multidisciplinary teams, typically comprising sarcoma specialist surgeons, radiologists, 
medical and clinical oncologists, a specialist sarcoma histopathologist as well as specialist 
nurses and physiotherapists (12). Every patient with a soft-tissue sarcoma will require an 
individualised treatment plan and the management of newly-diagnosed sarcoma is not usually 
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straightforward, therefore, the therapeutic goals are improving survival, avoiding local 
recurrence, maximising function, and minimising morbidity. Treatment of STS is based on the 
size and grade, location of the tumour, and whether the tumour has metastasised. The options 
for treatment of STS are surgery, radiation therapy (local treatment), and chemotherapy 
(systemic treatment)(6).  
1.1.7.1 Surgery 
Surgical excision remains the cornerstone of therapy and is a dominant curative procedure with 
adjuvant (treatment given after the surgery to kill the remaining cancer cells) and neoadjuvant 
RT (treatment given before surgery) for STS in selected patients, except for those patients who 
are surgically inoperable or those who decline surgery if it entails unacceptable functional loss 
(43). The extent of surgery required, along with the optimum combination of radiotherapy, 
remains controversial, but the clinical and pathological factors of the specific tumour need to 
be considered by the surgeon to determine the treatment plan for individual patients. Therefore, 
increased understanding of sarcoma biology as the primary determinant of outcome has led to 
the decrease in radical amputations and the recognition of limb-sparing treatments, often using 
a multimodal team approach (12). 
A recent study at the Memorial Sloan-Kettering Cancer Centre highlighted the need for 
collaborative, inventive approaches for sarcoma patients, as it appears to have reached that 
level with current therapy (44). In recent years, several more accurate descriptions of the 
surgical margin have been used and it is common practice to classify margins as positive or 
negative. A positive margin has been defined as one in which tumour cells are present at, or 
within, 1 mm of the resection margin, but which is otherwise negative. In some reports, margins 
have been documented as grossly positive, microscopically positive, close (5 mm or smaller) 
or negative (45); in others as clear (> 10 mm), close (1–9 mm) or positive (46).  
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Low grade tumours are usually treated by surgical excision with excellent functional prognosis, 
whereas surgery or radiation alone is usually inadequate for the management of high grade 
tumours more than 5 cm in size, locally recurrent, deep in investing fascia, having previous 
inadequate surgery or positive margins, and certain sub-types such as leiomyosarcoma or 
malignant peripheral nerve sheath tumour (12).  
1.1.7.2 Radiotherapy  
External beam RT is the most widely used modality, since its practice in now routine, and its 
application is technically less complex. In a randomised prospective study, it was reported that 
local control, conservative surgery with external beam RT is as effective as amputation in high-
grade STS (47). RT is more commonly given post-operatively than pre-operatively. Post-
operative RT has the following advantages: the operation can be performed without delay, the 
surgical specimen and margins can be accurately histologically analysed, and, in the event of 
wide margins, RT can be omitted. Nevertheless, pre-operative RT may be favoured in efforts 
to reduce the tumour size before surgery, with a view to minimising the resection area, reducing 
the seeding of viable tumour cells over the operative field and reducing the treatment volume.  
However, a randomised trial comparing pre- and post-operative RT, with wound complications 
as an end point, found that pre-operative RT was associated with a greater risk of wound 
complications (48). Pre-operative RT and chemotherapy also cause tumour necrosis, thus 
confound histopathological typing and grading of the surgical specimen. Sequencing of RT 
with surgery has not been proved to provide a reliable benefit for outcome (49). Generally, pre-
operative RT is recommended for large tumours in a difficult location to reduce their size and 
to make conservative surgery possible (50).  
 
- 33 - 
1.1.7.3 Chemotherapy  
Chemotherapy has poorer results for sarcoma treatment, the effectiveness of neoadjuvant and 
adjuvant therapy for STS is still currently controversial, with little proof in the literature to 
support the use of either. However, it is considered for patients with high grade, large, and deep 
STS to improve patient survival based on the persisting poor survival outcome (50–60%, year 
survival) of high-risk STS patients, despite having good local disease control with surgery and 
radiotherapy (11).  
According to a meta-analysis of 14 randomised trials comprising a total of 1,568 patients, 
doxorubicin-based adjuvant chemotherapy appeared to significantly increase the time to local 
or distant recurrence, improving the overall recurrence-free survival rate in adults with 
localised resectable STS (51). Significant absolute benefits were 6–10% at 10 years, and there 
was some evidence of a trend towards improved overall survival without a clear improvement 
in overall survival. In an Italian randomised co-operative trial, patients with high grade or 
recurrent sarcoma of extremities were randomised to undergo post-operative chemotherapy 
with epirubicin and ifosfamide or observation alone. After a median follow-up of 59 months, 
the treatment did significantly better in median overall survival (75 vs. 46 months) and the 
disease free period (48 vs. 16 months) (52). 
In addition, there is further evidence of neoadjuvant chemotherapy benefitting survival in adult 
STS in the treatment of rhabdomyosarcoma because, unlike most sarcomas, great response 
rates are observed in this sub-type. The importance of neoadjuvant chemotherapy has been 
suggested, since it is sometimes possible to use the response of the sarcoma to such therapy as 
a guide for further treatment or for prognosis (53). A study conducted at the MD Anderson 
Cancer Center found that the sarcoma response to pre-operative chemotherapy gives reliable 
prognostic information, and can identify a sub-group of patients most likely to benefit from 
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conventional adjuvant chemotherapy or those who should be considered for second-line or 
experimental treatments (54).  
Furthermore, chemosensitivity varies significantly between sub-types. Although most STSs 
are generally resistant to chemotherapy, smaller tumours have a higher growth fraction and are 
potentially more chemosensitive, whereas the larger the tumour becomes, the more likely 
chemoresistant clones will spontaneously arise (53).  
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1.1.8 Types of soft tissue tumours studied in this thesis 
The focus of this study is on myxoid and myofibroblastic soft tissue tumours, which are well 
represented in our archival material of adult STS of extremities. 
1.1.8.1 Myxoid soft tissue tumours 
Myxoid soft-tissue tumours comprise a heterogeneous group of mesenchymal tumours 
characterised by the production of a copious extracellular myxoid matrix. Myxoid tissue is not 
a normal tissue in adults and is actively secreted by tumour cells in these lesions. It consists of 
a gelatinous mucopolysaccharide matrix of sulphated and non-sulphated glycosaminoglycans 
(55). Myxoid soft-tissue neoplasms encompass a heterogeneous group of benign, locally 
aggressive, and malignant lesions, commonly affecting the extremities. There is significant 
overlap in the clinical and pathologic characteristics of these tumours, making a precise 
diagnosis challenging. Current developments in understanding the genetic and molecular 
characteristics of these tumours have led to notable advances in their classification, diagnosis, 
and management. For instance, round cell liposarcomas have been reclassified as myxoid 
liposarcomas, and the myxoid variant of malignant fibrous histiocytoma has been reclassified 
as myxofibrosarcoma due to their similar cytogenetic profile (10, 56). The 4th edition of the 
WHO classification of tumours of soft tissue published in 2013, updating the former 2002 
classification, proposed many changes in soft-tissue tumour classification and reported new 
genetic and molecular data for the tumours (3). A simplified classification of myxoid soft-
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Low-grade fibromyxoid sarcoma 
Myxoinflammatory fibroblastic sarcoma 
Myxoid Liposarcoma 
Extraskeletal myxoid chondrosarcoma 
Ossifying fibromyxoid tumour 
Adapted from Baheti et al, 2015 (57) 
 
1.1.8.1.1 Myxofibrosarcoma (MFS) 
Myxofibrosarcoma, previously known as the myxoid variant of malignant fibrous 
histiocytoma, is now considered as a distinct entity (58). Myxofibrosarcoma usually manifests 
in the sixth decade, with equal sex predilection and most commonly affects the extremities. It 
may be localised in the subcutaneous tissue, dermis, and intermuscular or intramuscular planes 
(59). Unlike other soft-tissue sarcomas, which are well-defined tumours, myxofibrosarcomas 
have an ill-defined infiltrative margin with an ability for centrifugal spread along fascial and 
vascular planes, which predisposes them to inadequate resections and high recurrence rates in 
50–60% of cases. Local recurrence is associated with the resection margin and low-grade 
tumours can become high grade after recurrence, with a higher tendency for metastases (60, 
61). MRI is the imaging modality of choice for myxofibrosarcomas. MFS appear 
heterogeneous on both T1- and T2-weighted images and lesions are T2 hyperintense with ill-
defined infiltrative margins and inhomogeneous contrast enhancement (62). Metastases are 
more common in high-grade tumours, and lungs are most commonly affected. The differential 
diagnosis involves other myxoid neoplasms (e.g., myxoid liposarcoma and myxoinflammatory 
fibroblastic sarcoma), other soft-tissue tumours (e.g., undifferentiated pleomorphic sarcoma), 
and inflammatory conditions (e.g., nodular fasciitis) (63). The treatment of choice for 
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myxofibrosarcoma is wide surgical excision, with a 5-year survival rate in a recent study of 
158 patients of 77%  (60, 63). 
1.1.8.1.2 Myxoinflammatory Fibroblastic Sarcoma (MIFS) 
Myxoinflammatory fibroblastic sarcoma is a rare low-grade sarcoma first described in 1998 
independently by three separate groups (64-66). It can affect both men and women equally, 
and all age groups. It characteristically involves the extremities and is often termed “acral 
myxoinflammatory fibroblastic sarcoma.” It shows four components on pathologic analysis, 
proliferative fibroblasts (spindle cells), myxoid matrix, inflammatory components, and atypical 
giant cells. In the WHO classification, it is described as being characterised by the translocation 
t(1;10) (3, 10). Patients commonly present with a painless slowly growing mass, but some may 
present with pain or tenderness. On imaging, these tumours are predominantly subcutaneous, 
with well- or ill-defined and infiltrative lesions frequently located along the tendon sheath (67). 
Local recurrence is common, occurring in 28–51% of cases, while metastases are rare. A recent 
retrospective study of 104 cases described a single case of metastasis and 51% local recurrence 
in the 59 patients with follow-up (68). Due to the infrequent incidence of distant metastases, 
the WHO classification has introduced a new term for them, “atypical myxoinflammatory 
fibroblastic tumour,” (10). Wide surgical excision of the tumour is the standard treatment, with 
a negative resection margin correlating with decreased recurrence (68). 
1.1.8.1.3 Fibromyxoid sarcoma (FS) 
Low-grade fibromyxoid sarcoma was first described by Evans in 1987 (also known as Evans 
tumour). It is a rare tumour that equally affects middle-aged men and women, commonly 
involving the extremities, trunk, and deep soft tissue (69, 70). Although FMS is characterised 
by relatively benign pathologic characteristics consisting of bland spindle cells with intermixed 
myxoid and fibrous stroma, it reveals aggressive behaviour with high rates of recurrence and 
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metastases (70). According to the recent WHO classification, MUC4 is a very sensitive and 
specific immunohistochemical marker for low-grade fibromyxoid sarcoma. Also, the presence 
of translocation t(7;16) and the formation of FUS/CREB3L2 fusion gene are also specific 
markers (3). Imaging reveals features consistent with the tumour’s fibrous and myxoid content, 
with MRI showing the fibrous component to be T1 and T2 hypointense and the myxoid 
component to be T1 hypointense and T2 hyperintense (71). Wide surgical excision is the 
treatment of choice, local recurrence is common in the form of multiple lesions, and metastases 
usually affect the lungs (70).  
1.1.8.1.4 Intramuscular Myxoma 
Intramuscular myxoma is the most common benign myxoid tumour consisting of abundant 
myxoid stroma interspersed with benign spindle cells. Women are affected more commonly 
than men (mean patient age, 50–60 years). Although they are most frequently intramuscular 
(82%), they can also be intermuscular or subcutaneous. The lower limb is the most common 
site affected and patients typically present with a slowly growing painless mass. Association 
with fibrous dysplasia has been reported in Mazabraud syndrome, which is characterised by 
multiple myxomas with associated (usually polyostotic) fibrous dysplasia (72-74). On MRI, 
the lesions are well circumscribed with smooth or slightly lobulated margins, homogeneously 
hypointense in T1-weighted images, and extremely hyperintense in T2-weighted images, 
similar to water (75). The choice of treatment for intramuscular myxoma is wide surgical 
excision, with recurrence being rare (72).  
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1.1.8.2 Fibroblastic/Myofibroblastic soft tissue tumours 
Tumours and tumour-like lesions of myofibroblasts may present a diagnostic challenge 
because of the uncertainties in identifying the myofibroblast, its attributes place it midway 
between a fibroblast and a smooth muscle cell, and since it appears capable of functional and 
phenotypic modulation (76). The main features of the myofibroblast include a spindled or 
stellate morphology; immunostaining for a-smooth muscle actin and the extra domain (76, 77).  
However, since most diagnostic tumour pathology is based on phenotypic features of the 
excised lesion, it is an unavoidable fact that a wide range of soft tissue tumours show 
convincing myofibroblastic features. This type of lesion can be divided into four main groups: 
1) the family of reactive fasciitis-like lesions, 2) a group of benign lesions (e.g., 
myofibrolastoma and dermatomyofibroma), 3) the locally aggressive fibromatoses (either 
superficial or deep fibromatosis) and, finally, 4) sarcomas showing myofibroblastic 
differentiation, the latter including myofibroblastic sarcoma (77, 78).  
1.1.8.2.1 Myofibroblastic sarcoma (MS) 
Myofibrosarcomas (myofibroblastic sarcomas) are rare neoplasms which are difficult to 
diagnose because myofibroblasts and fibroblasts appear morphologically similar in H&E 
sections, and reactive and neoplastic myofibroblasts, as well as some smooth muscle tumours, 
can be immunophenotypically indistinguishable. Myofibrosarcomas display a range of 
differentiation. Low- and intermediate-grade myofibrosarcomas are morphologically similar, 
and are distinct from pleomorphic myofibrosarcomas, which are high-grade neoplasms 
formerly classified as malignant fibrous histiocytomas. Other low-grade malignant tumours 
with myofibroblastic differentiation are inflammatory myofibroblastic tumours and infantile 
fibrosarcoma, which have specific genetic rearrangements and are not usually designated as 
myofibrosarcomas (76). The age range of patients with low-grade myofibrosarcoma (LGM) is 
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4–75 years, with a slight male predominance. The tumours range in size from 1.5 to 17 cm and 
most commonly occur in the head and neck region, proximal extremities and trunk, with 
occasional cases in the abdomen or pelvis (79). LGM usually arise in deep soft tissue, but some 
occur in the subcutis or submucosa. Although there can be partial circumscription, the growth 
pattern is predominantly infiltrative, in a fascicular, sheet-like, or occasionally storiform 
arrangement. Mitotic activity is variable but abnormal forms are usually absent (76). LGM are 
immunoreactive for actin (a-SMA and muscle-specific) in a multifocal pattern, fibronectin,  
calponin and less commonly (and more focally), desmin. Cytokeratin, epithelial membrane 
antigen (EMA), S100 protein and CD34 are almost always negative (80, 81). About a third of 
LGM recur locally, especially following incomplete excision. Metastasis, sometimes after a 
long period, has been reported in approximately 10% of published cases, usually to lung, but 
occasionally to other locations. These tumours are best managed by surgical excision, with the 
aim of achieving tumour-free resection margins (76, 77). 
Pleomorphic high-grade myofibrosarcomas (PHGM) are pleomorphic sarcomas which display 
only fibroblastic and myofibroblastic differentiation. They are not identified in the WHO 2002 
classification as a separate entity from pleomorphic malignant fibrous 
histiocytoma/undifferentiated pleomorphic sarcoma since they are morphologically 
indistinguishable, and immunohistochemistry or electron microscopy are required for their 
identification. There is, however, evidence that myofibroblastic differentiation in pleomorphic 
sarcomas is associated with more aggressive behaviour (82). Most PHGM arise in deep soft 
tissue in adults, predominantly in lower limb and trunk, with occasional cases in the head and 
neck (76). 
Macroscopically, PHGM are large solid tumours with haemorrhage and necrosis. 
Histologically, they are composed of pleomorphic spindles and polygonal or large epithelioid 
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cells arranged in fascicular and storiform patterns, with frequently abnormal mitotic activity. 
PHGM are high-grade sarcomas with recurrence in a third of cases and metastasis in over 70%. 
These tumours, like pleomorphic sarcomas with myogenic differentiation, have a poorer 
outcome than undifferentiated sarcomas (77, 82). 
1.1.8.2.2 Fibromatosis 
The term fibromatosis includes a broad range of morphologically related lesions which are 
divided into superficial and deep subgroups. Superficial (fascial) fibromatoses include palmar 
fibromatosis (Dupuytren contracture), plantar fibromatosis (Ledderhose disease), penile 
fibromatosis (Peyronie disease) and knuckle pads (76). The lesions in this group are 
characterised by their small size, slow growth, origin from fascia/aponeurosis and less 
aggressive behaviour. Deep (musculoaponeurotic) fibromatoses include extra-abdominal 
fibromatosis (extra-abdominal desmoid), abdominal fibromatosis (abdominal desmoid) and 
intra-abdominal fibromatosis (intra-abdominal desmoid), which can be further subdivided into 
pelvic and mesenteric fibromatosis and Gardner syndrome. The deep fibromatoses arise from 
deep structures, attain large size and have relatively more rapid growth (83). 
Histologically, fibromatoses are un-encapsulated spindle cell lesions with an infiltrative growth 
pattern. The cells are embedded in a collagenous stroma, arranged in long sweeping fascicles. 
The cells show no pleomorphism and mitotic figures are rare. The immunophenotype is 
positive for MSA and SMA and negative for desmin, h-caldesmon, and S-100. Seventy to 75% 
of cases show positivity for β-catenin (76, 84). The best method of treatment is excision by 
surgery. However, adjuvant therapy should be considered for cases with positive surgical 
margins, multiplicity of the tumour, inoperable tumours and severe adhesion (85).  
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1.1.9 The Microenvironment in Soft Tissue Sarcoma 
The microenvironment of neoplasms is comprised of multiple stromal cell types and 
extracellular matrix proteins in addition to the cancer cells. Carcinomas are composed of two 
compartments, a stromal compartment of fibroblasts and myofibroblasts and an epithelial 
compartment of malignant epithelial cells. The stromal compartment is usually involved in 
functional and structural support of tumour growth (86). This desmoplastic benign stroma 
accounts for 30–90% of the specimens. Both compartments contribute to the tumour matrix 
regarding their respective gene products. In contrast, sarcomas mainly have only one 
compartment, the malignant mesenchymal cell that largely produces the sarcoma matrix and 
contributes essentially to its gene products. Although sarcomas also contain a benign stromal 
part, this component is often observed to be 1% of the specimens. Hence, the predominant 
compartment in sarcomas is comprised of the malignant mesenchymal cells (87).  
These mesenchymal cells produce extracellular matrix (ECM) which is defined as a network 
of molecules, mostly proteins and carbohydrates which bind cells together. The main function 
of the ECM is to provide support and anchorage to cells. Furthermore, its components help in 
modulating other cell functions such as development, migration and proliferation (88). The 
ECM has various components including collagens, proteoglycans, hyaluronans, glycoproteins, 
elastin, fibronectins and laminins (89). Synthesis and degradation of the ECM is performed by 
a specialised function of mesenchymal cells, the matrix being the result of the balance between 
production and breakdown. However, biomechanical and biochemical signalling systems are 
integrated in this process. Biomechanical loading directs mesenchymal physiology, that is, 
differentiation, proliferation, cell shape and matrix constitution, whilst biochemical signalling 
coordinates the attachment and disconnection of adhesions according to other cellular activities 
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such as growth and proliferation. The cell matrix interacts via transmembrane receptors which 
are generically known as cell adhesion molecules (CAMs) such as integrin receptors (90). 
In 1960, it was described how a primary tumour of sarcoma can evade the anticancer immune 
response by establishing an immune-privileged microenvironment (91). Then in the 1970s, 
Juda Folkman proposed that angiogenesis is essential for solid tumour growth (92). The 
significance of tumour cell intravasation into the vascular system has especially been indicated 
in sarcoma, where vascular invasion, as determined by the presence of tumour cells within any 
location having an endothelial lining, has been recognised as a prognostic factor for metastasis 
(93). Tomlinson et al. (1999) reported that the pattern of angiogenesis is different between 
sarcomas and carcinomas (87), confirming that the capillaries in carcinomas are clustered in 
bursts within the tumour stroma and that the microvessel density in these bursts can be used as 
a prognostic factor. In contrast, microvessel density in sarcomas was revealed to have a more 
homogeneous appearance. A more recent study reinforced this pattern of angiogenesis 
illustrating that angiogenesis was diffuse in high-grade STS and only present in 33% of the 
investigated specimens (94).  
1.1.9.1 Hypoxia in STS 
Hypoxia and oxidative damage is a common characteristic of many solid tumours owing to 
aberrant vascular function and rapid cell division. Tumour cells can survive under conditions 
of low oxygenation by initiating adaptive responses to match oxygen supply with metabolic, 
bioenergetic and redox demands (95). Clinical and experimental studies have long 
demonstrated that tumour hypoxia is associated with increased malignancy, poor prognosis, 
and resistance to radiation and chemotherapy (96). Patients with the most hypoxic soft tissue 
sarcomas have a poorer disease-specific and overall survival, with an increased likelihood of 
metastasis (97, 98).  
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Tumour cell adaptations to hypoxia largely depend on the transcription factor, hypoxia-
inducible factor (HIF), which is activated in low oxygen conditions and is inactive when 
oxygen is sufficient (99). HIFs form heterodimeric complexes constituted of an oxygen-liable 
α subunit and a stable β subunit. Together these subunits bind hypoxia response elements 
(HREs) on several hundred genes that facilitate the adaptation to hypoxia (100) . Mammals 
have three isoforms of HIFα, of which HIF1α and HIF2α are the best characterised. HIF1α is 
ubiquitously expressed, whereas HIF2α and HIF3α are selectively expressed in specific tissue 
types including vascular endothelium and cells of myeloid lineage. HIF activity is controlled 
by the stabilization of HIF1α and HIF2α protein subunits, which increases as cells become 
more hypoxic (100). Like other solid tumours, as sarcomas relinquish their blood supply, 
hypoxia stabilises HIF1α and HIF2α, which bind to HIF, driving the transcription of important 
genes in many aspects of cancer biology including angiogenesis, epithelial-mesenchymal 
transition, invasion, metastasis, and resistance to radiation therapy and chemotherapy (101). 
Based on genome-wide chromatin immunoprecipitation studies, the estimated number of direct 
HIF target genes is greater than 800 (102).  
Finally, there are many recent reports of a regulatory link between the cell oxygen sensors and 
heat shock pathways. The activation of HSPs is critical to adaptation to hypoxia and expression 
of inducible HSPs is regulated by heat shock factors (HSF), in particular HSF-1 (103). Baird 
et al. showed that HSF transcription is up-regulated during hypoxia due to direct binding by 
HIF-1 to HIF-1 response elements in a HSF intron. This rise in HSF transcripts is important 
for the full induction of HSPs during hypoxia and reoxygenation (104). HSPs give transient 
protection from stress, acting as chaperones by regulation of protein folding to ensure accurate 
conformation and translocation (105).  This may explain the ability of malignant cells to sustain 
protein homoeostasis even in the harsh hypoxic microenvironment of the tumour. 
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Consequently, HSPs may account for the ability of tumour cells to tolerate genetic variations 
that would otherwise be lethal (103). 
1.2 Heat Shock Proteins (HSPs) 
1.2.1 Discovery of Heat Shock proteins (HSPs) 
Among the many changes in cellular activity and physiology, the most remarkable event in 
stressed cells is the production of a highly conserved set of proteins, the heat shock or stress 
proteins (106). Intensive research into the structure and function of heat shock proteins (HSPs) 
has been ongoing for the past 30 years. They are of considerable interest since they have been 
shown to have a pivotal role in cell cycle progression and cell death (apoptosis), as well as 
being involved in many disease processes. 
The term heat shock protein (HSP) is used to describe several families of proteins whose 
expression is induced by hyperthermia. The first description of this phenomenon arose from 
the observation that Drosophila larvae exhibited a novel puffing pattern on their giant salivary 
gland chromosomes when they were exposed to higher temperatures (107). Subsequently, 
Ritossa's early experiments demonstrated that these chromosome puffs were also induced in 
the midgut and hindgut of the larvae, indicating that the heat shock response was not tissue-
specific. Furthermore, the same puffing pattern could be generated in isolated salivary glands 
by treatment with 2,4-dinitrophenol, sodium salicylate, sodium azide and release from anoxia. 
These early observations implied two important features of the heat shock response, firstly, the 
universality of the response in all cell types (not tissue-specific), and secondly, the variety of 
cellular stresses which will induce this pattern of specific gene expression (107). 
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For many years, all research on heat shock gene expression was performed solely using 
Drosophila larvae and it was not until the late 1970's that the ubiquity of the heat shock response 
was demonstrated. The same typical pattern of gene expression in response to heat shock was 
then shown in chicken embryo fibroblasts (108) and Escherichia Coli (109), and subsequently 
in yeast (110) and plants (111). The heat shock response has since been observed in all 
organisms examined, from archaebacteria to eubacteria, yeasts, plants, invertebrates and 
vertebrates, including humans.  
Examination of the nucleic acid sequence of heat shock genes from distant species and protein 
analysis using monoclonal antibodies has demonstrated that the heat shock proteins are among 
the most abundant and highly conserved proteins in nature (112). Although the term ‘heat 
shock protein’ is still used widely, many environmental and pathophysiological stresses have 
been shown to induce the response, including heavy metals, ethanol, amino acid analogues, 
fever and viral or bacterial infection (113). For this reason, the heat shock proteins are 
frequently referred to as ‘stress proteins’. It should be noted that many of these inducers share 
a capacity to cause protein denaturation, a fact which hints at the major functional role of the 
heat shock proteins as molecular chaperones. This function is vital to the cell, both under 
normal circumstances and following cellular stress. Recently, the term ‘proteostasis’ was used 
to describe the function of chaperones controlling protein synthesis, folding, trafficking, 
aggregation, disaggregation, and degradation (114).  
1.2.2 Nomenclature of HSPs 
Some confusion still arises in the literature regarding the nomenclature used to describe heat 
shock proteins, molecular chaperones and a sub-group of molecular chaperones known as 
chaperonins. Heat shock proteins are also frequently referred to as ‘stress proteins’, a term 
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which reflects the fact that HSP expression is induced by a wide variety of cellular insults other 
than hyperthermia (113), and is therefore perhaps a more appropriate nomenclature.  
Molecular chaperones are defined as a family of unrelated classes of protein which mediate the 
assembly of other cellular polypeptides, but are not components of the final functional 
polypeptide structure (115). As will be described, the ability of molecular chaperones to 
interact with other cellular proteins is vital to the cell, both during normal cell growth and when 
the cell is subjected to some form of environmental or pathophysiological insult. Many, but not 
all, molecular chaperones can be classified as heat shock proteins since their expression can be 
induced by hyperthermia and a variety of other cellular stresses. Similarly, most heat shock 
proteins are now known to perform a molecular chaperone function.  
The term chaperonin is used to describe a specific sub-group of the molecular chaperones, 
comprising a class of sequence-related molecular chaperones found in all bacteria, 
mitochondria and plasmids examined so far (116). One of the remarkable features of the 
chaperonins is the very high degree of structural and functional homology between members 
of this group. Chaperonins are essential components of the cellular chaperone 
mechanism. Chaperonins have two-ring assemblies that comprise a central cavity to which 
unfolded polypeptides attach and where they reach the folded state. Hence, chaperonins able 
to prevent off-pathway reactions and help productive protein folding to the original state in 
ATP-dependent manner (117) 
Finally, client proteins transiently non-covalently bind to HSP and this binding may be 
necessary for their function (118). To date, more than 200 HSP client proteins have been 
identified, involving almost all vital cellular activities and processes, including cell growth, 
proliferation and cell survival (119). For instance, HSP90 clients range from signalling protein 
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kinases through steroid hormone receptors and small G proteins to enzymes and components 
of the telomerase complex, and the list continues to grow (120). 
1.2.3 Function of heat shock proteins as molecular chaperones 
As stated above, HSPs are part of a group known as ‘molecular chaperones’, a nomenclature 
which clearly defines the function of these molecules which accompany unfolded proteins and 
polypeptides during their cellular transport in normal metabolism and help protect these 
proteins and polypeptides whenever they are subjected to stresses that may cause them to 
unfold (121). 
A more detailed definition is that a ‘molecular chaperone’ is a protein that binds to and 
stabilises an otherwise unstable conformer of another protein, and by controlled binding and 
release of the substrate protein facilitates its correct fate in vivo, thus allowing folding, 
oligomeric assembly, transport to and between subcellular compartments, or controlled 
switching between active/inactive conformations (122). Molecular chaperones also bind to and 
prevent aggregation of denatured or partially folded proteins, assisting the correct folding of 
these proteins (123).  
Under conditions of normal cellular growth, the many vital functions which are served by 
molecular chaperones derive from their ability to recognise and modulate the state of folding 
of other cellular proteins (112, 116). In the cell, nascent polypeptide chains emerge from 
ribosomes as unfolded linear chains and a comparable situation exists when polypeptide chains 
are transported across intracellular membranes in an extended state. In such an extended or 
partially folded state, hydrophobic surfaces become exposed, raising the possibility of aberrant 
inter- or intramolecular interactions and the formation of polypeptide aggregates. The major 
role of molecular chaperones appears to be the prevention of these incorrect intermolecular 
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associations between unfolded polypeptide chains, thereby preventing their aggregation and 
assisting in the maintenance of polypeptide chains in a translocation-competent state during 
transport across intracellular membranes (122). 
During stress conditions, partially denatured misfolded proteins accumulate and their exposed 
hydrophobic regions lead them to aggregate. HSPs aid to prevent the change of the 
conformation of other proteins, protecting incorrectly folded proteins against aggregation. 
Upon recovery, they help the refolding of misfolded proteins, but they also can facilitate in the 
proteasomal degradation of peptides that cannot be refolded (124) (Fig. 1).  
 
 
Figure 1.1 Chaperone functions of HSPs. Adapted from Toth et al., 2015 (125). During stress 
conditions, misfolded proteins accumulate and form large aggregates. However, some HSPs (like 
HSP70/HSP40 complex) can bind to misfolded proteins preventing their aggregation and facilitating 
their refolding. On the other hand, they also can assist in the proteosomal degradation of proteins that 
cannot be refolded.    
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1.2.4 Family of heat shock proteins 
The expanding of members in the different HSP families and the inconsistencies in their 
nomenclature and classification have always led to confusion. Originally, mammalian HSPs 
were classified according to their molecular size (126). However, Kampinga et al.  proposed 
new guidelines for the nomenclature and classification of human HSP families. Consequently, 
human HSPs are classified into the following groups: HSPB (small HSP), DNAJ (HSP40), 
HSPA(HSP70), HSPC (HSP90), HSPH (HSP110) and the chaperonin families HSPD/E 
(HSP60/HSP10). This nomenclature is based mainly on the more constant nomenclature 
assigned by the HUGO Gene Nomenclature Committee and adopted in the National Centre of 
Biotechnology Information Entrez Gene database for the heat shock gene (127). Table 1-7 
presents a summary of these proteins, their cellular location and function. 
High molecular weight HSPs are ATP-dependent chaperones, while small HSPs act in an ATP-
independent fashion (128), with each HSP family member being expressed constitutively or 
regulated inductively and is targeted to different subcellular compartments (129). Constitutive 
activation of HSPs may occur in cells even in the absence of environmental stressors. For 
example, HSP90 can constitute up to 1% of total cellular protein in unstressed cells (130) 
indicating that these proteins have a role in maintaining protein conformation even under 
normal conditions. 
Table 1.7 Summary of human HSPs according to their molecular weight, location and function. 




Small HSPs HSP10 10/102 Mitochondria 
HSP27 22/205 Cytosol/Nucleus 
HSP40 38/340 Cytosol 
 
- 51 - 
HSP40/DNAJ 
family 
DNAJA1 44/397 Nucleus/Cytosol 
DNAJA3 52/480 Cytosol 
CY40 40/370 Cytosol 
HSP60 HSP60 61/573 Mitochondria 
CCT1 60/556 Cytosol Cytoskeleton 
HSP70 HSP70 70/641 Cytosol 
HSP70-2 70/641 Cell surface 
HSP72 70/639 Cytosol 
HSP73(HSC70) 70/646 Cytosol 
Grp78 72/654 Endoplasmic reticulum 
HSP90 HSP90 86/732 Cytosol 
HSP90B 84/724 Cytosol 
Grp97 92/803 Cytosol/Endoplasmic 
reticulum 
TRAP1 75/704 Mitochondria 
(adapted from Khalil et al., 2011 (126)) 
 
1.2.4.1 HSPB (small heat shock protein) family 
Small heat shock proteins (HSPB) are present in all type of cells and play vital roles in cell 
biology. They are fundamental components of the cellular protein quality control system, 
acting as the first line of defence against conditions that influence protein homeostasis and 
proteome stability (131). The small heat shock proteins have molecular weights in the range 
16–40 kDa and are characterised by a conserved C-terminal domain of 100 amino acids, 
referred to as the alpha-crystallin domain (ACD) (132). From a structural point of view, HSPBs 
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can exist in the form of monomers and dimers, but can also assemble into large multimeric 
complexes that vary in size and contain up to 24–40 subunits. Association of monomers into 
large complexes, as well as dissociation of large oligomers into dimers and monomers, is 
modulated by sHSP post-translational modification, including phosphorylation, which, in turn, 
regulates sHSP functions (133). The mammalian HSPB family contains at least 10 members, 
the best-studied of which are HSPB1 (HSP27), HSPB4 (αA crystallin) and HSPB5 (α B-
crystallin) (133, 134). Both HSPB1 and HSPB5 are constitutively expressed in a variety of 
tissues, however, their expression is up-regulated under stress conditions and in several 
diseases (134). Some members, like HSPB5, HSPB1, HSPB2 (MKBP), are highly expressed 
in cardiac and skeletal muscles (135). 
Small HSPs functions are very diverse including chaperone-like activity and modulation of 
cytoskeleton stability. As a consequence of their role as chaperones towards diverse clients, 
which influences client fate (refolding or degradation) and due to their role as stabilizing agents 
of the cytoskeleton, sHSPs participate indirectly in the regulation of complex processes such 
as the response and adaptation to cell stress, thermotolerance, cell differentiation, cell 
movement, cell apoptosis, and development (136, 137). Thus, malfunction of HSPs can have 
adverse effects in many diseases, causing a wide range of pathologies including 
cardiomyopathy, myofibrillar myopathy, motor neuron diseases and cataracts (131). As the 
ATP level of the cells can reduce severely during stress conditions, these HSPBs act in an ATP 
independent manner. After stress recovery, when the ATP level has been returned, the 
sequestered damaged proteins can be transferred to ATP-dependent chaperone, like the 
HSPA/DNAJ (HSP70/HSP40) complex, which can facilitate the refolding or the degradation 
of these proteins (136, 138, 139). 
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1.2.4.2 DNAJ (HSP40) family 
The DNAJ (HSP40) family is the largest human HSP family consisting of at least 50 members 
(127) characterised by a conserved, usually N-terminal J-domain, through which they bind to 
HSPA (HSP70) proteins. They are fundamental in protein folding, refolding and translocation 
as they are responsible for the stimulation of HSPA ATPase activity (140). DNAJ proteins can 
bind substrate peptides and transfer them to HSPA, while the J-domain facilitates ATP 
hydrolysis. Several members of DNAJ family also regulate the activity of other HSPs, like 
HSPC (HSP90) proteins. They can be found in various cell compartments, such as cytosol, 
nucleus, endoplasmic reticulum (ER), mitochondria, endosomes and ribosomes, with some of 
them showing tissue specific expression (140). 
1.2.4.3 HSP60 (chaperonin) family 
The chaperonin family of HSPs comprise two major subgroups, the GroEL (hsp60) family and 
members of the TCP-1 ring complex (TRiC) family, both of which have an essential function 
in promoting the ATP-dependent folding of proteins during normal growth and following 
cellular stress (127). Members of the GroEL family are found in mammalian mitochondria, 
where their major function is to promote the folding and assembly of imported proteins and the 
binding of heat-denatured mitochondrial proteins (112). The TRiC chaperonins are found in 
archaebacterial and the eukaryotic cytosol, and although fewer studies on the function of this 
subgroup have been reported, the available data on the structure of these proteins suggests that 
they are also important in providing a folding compartment for polypeptide assembly. 
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1.2.4.4 HSPA (HSP70) family 
Members of this family are highly conserved ATPases, identified in both prokaryotes and most 
compartments of eukaryotic cells. The human HSP70 family consists of 13 members with 
similar structural and functional properties. HSPA1A (HSP70-1) and HSPA1B (HSP70-2) only 
vary in two amino acids, and probably because they are totally interchangeable proteins, are 
usually referred to as HSPA1 (HSP70) (127). In eukaryotes, there are four essential proteins, 
constitutively expressed HSC70 (HSP73 or HSPA8), mitochondrial mtHSP70, endoplasmic 
reticulum-localised GRP78/Bip and stress-inducible HSP70 (HSP72 or HSPA1) which is 
simply called HSP70 (141). 
They have two main functional domains, an N-terminal ATPase-binding domain (ABD) 
responsible for substrate binding and refolding, and a C-terminal peptide-binding domain 
(PBD) to help the release of the client protein after ATP hydrolysis (142). HSP70 chaperone 
activity is regulated by different co-chaperones, e.g. Hip, CHIP or Bag-1. These co-chaperones 
bind to HSP70 and modulate its chaperone function by enhancing or reducing HSP70 affinity 
for substrates through the stabilisation of the ADP or ATP bound state of HSP70 (119). 
1.2.4.5 HSPC (HSP90) family 
HSPC (HSP90) family is the most well studied member of the heat shock protein families. 
Genetically, this family encodes five members (HSPC1-5) (127), which are the most abundant 
proteins in cells, producing 1–2% of the total cellular proteins. They can be found in different 
cell compartments such as cytosol, ER and the mitochondria (143). The most important 
members of the HSP90 family are inducible HSP90α (HSP90AA1) and constitutive HSP90β 
(HSP90AB1) isoforms (now also called HSPC1 and HSPC3, respectively), which are 
expressed by two distinct genes whose protein products are mainly cytoplasmic. The HSP90α 
was determined to be constitutively expressed at a low level, but strongly heat inducible. In 
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contrast, the HSP90β gene is expressed constitutively at a much higher level and is only weakly 
inducible following a heat shock (144). Members of the HSPC family are homodimers 
composed of three functional domains, an amino-terminal ATP binding domain, a charged 
middle linker domain, and a carboxyl-terminal dimerization domain. They are an ATP 
dependent molecular chaperon and there are over 200 HSP90 identified “client proteins” 
reported to interact with HSP90, compromising a variation of functional pathways for cell 
proliferation, growth and survival (144).  
1.2.4.6 HSPH (HSP110) family 
The human HSPH (HSP110) family contains three cytosolic and one ER specific members. 
They are highly homologous to HSPA proteins, but they have a longer linker region between 
the N-terminal ATPase domain and the C-terminal peptide-binding domain (127). A HSP110 
family member has been described as a co-chaperone for HSP9. HSPH family members also 
cooperate with HSPA (HSP70) in protein folding, as they function as nucleotide exchange 
factors, removing ADP after ATP hydrolysis (145). 
1.2.5 Transcriptional regulation of HSP activity 
The induction of the expression of genes encoding HSPs in response to various stresses is 
regulated by a family of transcription heat shock factors (HSFs). Under stress conditions, these 
regulators activate the heat shock genes by binding to the heat shock elements found in the 
promoter region of the HSP genes. In humans, six types of HSFs have been identified namely 
HSF1, HSF2, HSF4, HSF5, HSFX and HSFY (146). HSF3 has been described for mice but not 
humans (147). The earliest-discovered and most widely studied HSF is HSF1, which plays a 
fundamental role in the heat shock response (148). HSF1 is expressed in almost all tissues and 
cell types, activated in response to different cellular stressors. while other members of the HSF 
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family are mainly involved in normal development, cell differentiation and life span regulation 
(149). HSFs are varied in size, but all of them contain an N-terminal DNA-binding domain, a 
hydrophobic oligomerization domain as well as a C-terminal transactivation domain (148). 
The inactive, monomeric form of HSF is separated in the cytoplasm of unstressed cells by 
binding to various HSPs, such as HSPC (HSP90), HSPA (HSP70) or DNAJ (HSP40). During 
stress conditions, the amount of partially denatured proteins gradually increases, and these 
proteins upon binding to HSPs, release HSFs. The released HSFs undergo trimerisation, 
phosphorylation and translocate to the nucleus, where they bind to its target sites (heat-shock 
elements) in the regulatory region of heat shock induced genes and activate them. This 
activation is fast, the DNA-binding form of HSF can be identified within minutes following 
heat treatment (150). The activation of heat shock genes leads to increased expression of HSPs, 
which then associate with HSF. In this way, HSPs negatively regulate the expression of heat 
shock genes via an auto-regulatory loop. For example, the activity of HSF1 is down-regulated 
by the binding of HSP70 to its transactivation domain, resulting in the repression of heat shock 
gene transcription. Also, there is an interaction between HSP-binding factor 1 (HSPB1) with 
the active HSF1, thereby inhibiting the capacity of HSF-1 to bind DNA (148, 150). 
 
 
- 57 - 
 
Figure 1.2 Activation of the heat shock protein (HSP) by specific stimuli and their protective effect. 
Adapted from Shi et al., 1998 (150). 
 
Figure 1.3 Transcriptional regulation of heat shock proteins. Adapted from Toth et al., 2015 
(125). The inactive form of HSF is segregated in the cytoplasm of unstressed cells by binding to different 
HSPs, such as HSPC (HSP90) or HSPA (HSP70). During stress conditions, the amount of denatured proteins 
increases (1), which can bind to HSPs, thus releasing the HSFs (2). The released HSFs undergo trimerization, 
phosphorylation and translocate to the nucleus (3), where they bind to the HSE of the promoters of heat shock 
induced genes and activate them (4). The newly synthesized HSPs than associate with HSF, thereby negatively 
regulate their own expression via an autoregulatory loop (5). On the other hand there is an alternative, 
membrane-associated “thermosensor” that can initiate heat shock gene activation. During heat stress, the 
membrane fluidity rapidly increases (6), which can activate stress sensing and signalling pathways leading to the 
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1.2.6 The role of heat shock proteins in cancer  
There is overwhelming evidence that heat shock proteins are expressed at elevated levels in a 
range of cancers and form an encouraging environment that is essential for tumour 
development (151, 152). HSP expression appears essential in many of the distinctive traits of 
malignant cells as described by Douglas Hanahan and Robert Weinberg in their article in 2000, 
“The hallmarks of cancer” , including uncontrolled proliferation, insensitivity to anti-growth 
signals, avoidance of cell senescence, evading apoptosis, as well as the acquisition of powerful 
capacities for angiogenesis and metastasis (153, 154).  
 
1.2.6.1 Tumour proliferation and avoidance of senescence 
Cell proliferation in adult tissues is not a default state and most cells have long ceased growing 
at this stage. In cancer, growth control is deregulated and proliferation resumes (155). Most of 
the receptors and enzymes that constitute the cascade are oncogenic when expressed at elevated 
levels or activated through mutation. Many of these proteins are clients of HSP90, therefore, 
amplification of HSP90 is permissive for unrestrained proliferation (156). Thus, HSP90 
chaperone complexes maintain the signalling circuitry that underlies the capacity of many 
cancers for independent growth (157). There is some suggestion that HSP70 is also required in 
a similar way, because inactivation of this chaperone led to inhibition of proliferation in murine 
mammary tumour cells (158). 
HSPs contribute to limitless proliferation by avoidance of senescence. Normal cells resist 
transformation by having a limited number of permitted divisions (159). This system is based 
on the lack of replication of chromosome ends at each cell division; the capping structures at 
the chromosome ends become progressively shortened, leading to arrest of further division and 
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cell senescence (160, 161). Cancer cells evade the senescence program by deploying the 
enzyme telomerase, which replaces the shortening ends of telomeres (161). HSP90 binds to 
telomerase and is required for its efficient function (162), thus, HSP90 might deter senescence 
by chaperoning telomerase and overcoming the erosion of telomeres over time when expressed 
to high levels, as in cancer. 
In addition, one of the principal factors that controls the development of cancer is p53, a protein 
with a role in mediating growth arrest and apoptosis in response to DNA damage. Expression 
of HSP70 and HSP90 increases to high levels in tumours with mutated p53 and both 
chaperones may have roles in stabilizing the altered conformation of the mutant p53 (163, 164). 
Also, HSP27 and HSP70 inhibit the effector arm of the senescence pathway by reducing the 
effectiveness of p53 in promoting cell senescence (165, 166). P53 transcriptionally upregulates 
cell cycle protein p21, which directly arrests proliferation and this process is inhibited by high 
levels of HSP70 (167).  
1.2.6.2 Angiogenesis 
Under hypoxic conditions, tumour cells are able to deploy HIFs, proteins that can sense the 
low oxygen environment and mediate the expression of growth factors, such as vascular 
endothelial growth factor (VEGF), thereby increases the growth of the tumour capillary 
network and angiogenesis (168). 
Also, several critical mediators in this angiogenic signalling pathway, including HIF, VEGF-
receptor and Nuclear factor-κB (NF-κB) are dependent upon HSPs for their function (169). 
Indeed, HIF-1 is stabilised by HSP90 in hypoxic conditions (170). HSP27 becomes 
proangiogenic when released from tumour cells and can bind to receptors, stimulating VEGF 
transcription through an alternative pathway involving the factor NF-κB (171). 
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1.2.6.3 Invasion and metastasis 
Tumour metastasis is a complex process in which cancer cells acquire specific capabilities 
(154) and elevated expression of each of the HSPs strongly promotes metastasis. An increase 
in HSP90 is associated with metastasis, largely due its capacity to chaperone focal adhesion 
kinase, integrin linked kinase and the receptor tyrosine kinases, ErbB2 and MET (172). HSP90 
was found on the cell surface and in conditioned medium of tumour cells, where it acted as a 
molecular chaperone to help in the activation of matrix metalloproteinase-2 (MMP-2) leading 
to elevated tumour invasiveness. Activated MMP-2 protease digests many of the essential 
ECM components surrounding tumour tissue, thereby facilitating tumour invasion (172, 173).  
In addition, HSP27 expression also favours metastasis though its effects on a process known 
as the epithelial-mesenchymal transition (EMT), in which cells switch from a compact shape 
to a spindle shape and gain enhanced cell motility (174). 
1.2.6.4 Anti-apoptosis 
Two main pathways for apoptosis induction have been recognised, intrinsic and extrinsic. The 
hallmarks of the intrinsic pathway are mitochondrial involvement and the production of the 
‘apoptosome’. In the intrinsic pathway, cell death signals cause the release of the cytochrome 
complex (Cyt c) from the mitochondria, which then attaches to the apoptosis protease 
activating factor-1 (Apaf-1), inducing oligomerization and ultimate recruitment of procaspase-
9. Apoptosome formation results in the activation of caspase-9, which triggers the caspase 
pathway by activating the downstream caspase-3 (175). Cancer cells have been shown to 
deploy a range of mechanisms to evade apoptosis (176). Remarkably, HSP27, HSP70 and 
HSP90 have been shown to interact directly with protein intermediates in the apoptosis 
pathways and are potent inhibitors of apoptosis (176, 177). HSP27 inhibits apoptosis through 
its capacity to block multiple steps in these death pathways, including inhibiting cytochrome c 
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and SMAC Diablo release from mitochondria, as well as antagonizing caspases 3 and 9 (178, 
179). HSP70 is likewise a versatile inhibitor, blocking the c-jun kinase pathway of programmed 
cell death and interrupting cytochrome c release from mitochondria (177, 180). Also, HSP70 
functions at the post-mitochondrial level by interacting with the apoptosis-inducing factor 
(AIF) and Apaf-1 (181). HSP90 and its co-chaperones also modulate and mediate tumour cell 
apoptosis via interaction with Akt kinase, tumour necrosis factor (TNF) receptor, HER2/ErbB2 
receptor, and NF-κB (176, 182). 
The way that various HSPs behave in the cell death machinery is still controversial and the 
detailed signalling pathways that lead to apoptosis are far from being understood. However, 
HSPs 27, 70 and 90 are now established anti-apoptotic proteins (176, 177). 
1.2.6.5 Resistance to chemotherapy 
Since the cytoprotective effect of HSPs is essential for cancer cell survival, it is not surprising 
that HSPs targeted therapy is considered as a potential pharmacological intervention strategy 
for cancer treatment. To that end, there are currently thirteen HSP90 inhibitors being clinical 
evaluated in cancer patients (183). Most investigations to identify HSP90 inhibitors have 
concentrated on ligands binding to the N-terminal ATP-binding site, which interrupts HSP90’s 
ATPase activity and the ongoing ATP-dependent folding cycle. As this cyclic event requires 
multiple co-chaperone proteins, inhibition results in the destabilization, ubiquitination, and 
ultimately, proteasomal degradation of the client proteins simultaneously causing the 
disruption of multiple oncogenic signalling pathways. 
However, one of the crucial problems with HSP90 inhibition is the increase of HSP70 after 
treatment, which can reduce cell death induced by HSP90 inhibitors and therefore buffer their 
anti-tumour efficacy in the clinic. These disappointing results may be related to inherent HSP90 
inhibitors toxicity and induction of HSP70 by calcium mobilization and activation of the TGF-
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β signalling pathway. Thus, HSP70 inhibition combined with anti-HSP90 compounds may 
eliminate the toxic side-effects of HSP90 inhibitors, enhancing the synergistic efficacy for the 
treatment of cancer. 
1.2.7 Expression of studied HSPs (HSP27, HSP70 & HSP90) in various tumour 
types 
In the literature, there is overwhelming evidence that heat shock proteins are expressed at 
elevated levels in a range of cancers (126, 152). This thesis focuses on HSP27, HSP70, and 
HSP90, the most widely reported chaperones in the literature. 
1.2.7.1 HSP27  
HSP27 (HSPB1) is a member of the small HSP family and acts as an ATP-independent 
chaperone. The primary structure of HSP27 is highly homologous to other members of the HSP 
family, containing the conserved α-crystalline domain and differing in the C- and N-terminal 
regions. HSP27 is expressed in all human tissues (184), mainly residing in the cytosol (185). 
In the field of oncology, HSP27 has been found intracellularly and the extracellularly, with 
increased levels detected in various types of cancer such as ovarian, prostate, brain and breast 
cancers (126, 152, 186).  
1.2.7.2 HSP70  
The HSP70 superfamily consists of at least 13 members. There are four major proteins, 
constitutively expressed HSC70 (HSP73 or HSPA8), mitochondrial mtHSP70, endoplasmic 
reticulum-localised GRP78/Bip and stress-inducible HSP70 (HSP72 or HSPA1), simply 
referred to as HSP70 (127). The extensively studied inducible HSP70 (HSPA1A or HSP72) 
has ATP-dependent chaperone properties (187) and is over-expressed in various tumours such 
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as gastric adenocarcinomas (188), hepatocarcinoma (189) and oesophageal cancer (190). 
Myung et al. studied HSP70 expression in human tumour cell lines and showed that HeLa 
cells, osteosarcoma, A-673 (rhabdomyosarcoma), CaOv-3 (ovarian adenocarcinoma), as well 
as malignant melanoma expressed HSP70 (191).  
1.2.7.3 HSP90  
HSP90 belongs to another important class of the HSPC family and is a highly abundant ATP-
dependent chaperone protein expressed by all eukaryotic cells (127, 192). It accounts for 1–
2% of total cellular proteins, increasing upon induction from baseline levels to 4–6%. It has 
two main isoforms, HSP90α (inducible form) and HSP90β (constitutive form) (144). Like other 
HSPs, HSP90 over-expression has been related to the prognosis and evolution of neoplasia. 
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1.3 Thesis Hypothesis 
1.3.1 The Rationale of the current study 
Soft tissue sarcomas are a rare and a heterogeneous group of malignancies originating from 
mesenchymal tissue. The rarity of soft tissue sarcomas, coupled with their diversity, is 
challenging for researchers to understand their natural history, prognosis and management. 
Hence, further research is essential to understand the cellular and molecular variability of soft 
tissue sarcomas, which may provide insights into the clinical heterogeneity of the disease and 
its pathology. Among the many changes in cellular activity and physiology, the most 
remarkable event in stressed cells is the production of a highly-conserved set of proteins called 
heat shock proteins (HSPs). Intensive research into the structure and function of HSPs has been 
ongoing for the past 20 years. They are of considerable interest since they have been shown to 
have a pivotal role in cell cycle progression and cell death (apoptosis), and to be involved in 
many disease processes (152). In addition, they found to be increased in many solid tumours 
and haematological malignancies (126).  
Among the heat shock proteins, HSP27, HSP70 and HSP90 are the most commonly studied. 
They are potent anti-apoptotic proteins, associating with essential apoptotic factors, thereby 
blocking this cell death process at different levels (176). There are several reports about the 
prognostic role of anti-apoptotic HSP27, HSP70 and HSP90 in various tumour types. 
Furthermore, it has been reported that over-expression of HSPs is associated with poor 
prognosis, such as HSP27 in breast malignancy (193), HSP70 in pancreatic adenocarcinoma 
and HSP90 in gastrointestinal stromal tumours (194). According to Uozaki et al., the over-
expression of HSP27 has the strongest negative prognostic value for conventional 
osteosarcoma (195). Despite the importance of HSP activity in various tumours, little is known 
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about the role of HSPs in soft tissue sarcomas. In a proteomic study, Suehara et al. 
demonstrated that the expression levels of HSP27 were associated with histological grading 
and patient survival in leiomyosarcoma (196). Recently, Bekki et al. reported that HSP90 is 
highly expressed in undifferentiated pleomorphic sarcoma (UPS) using 
immunohistochemistry, concluding that it is a poor prognostic factor (197).  
1.3.2 Hypothesis 
Based on the literature review, given the importance of HSPs (notably HSP27, HSP70 and 
HSP90) in malignancies and their participation in different hallmarks of cancer, it is 
hypothesised that HSPs (particularly HSP27, HSP70 and HSP90) are highly expressed in 
myofibroblastic/fibroblastic sarcoma, and there is a relationship between overexpression of 
these HSPs and the prognostic clinical pathological features of soft tissue sarcomas.  
1.3.3 Null Hypothesis 
The hypotheses are individually or collectively not true. 
1.3.4 Aim & objective 
1.3.4.1 Primary aim 
The primary aim of the present study is to evaluate the expression of selected HSPs (HSP27, 
HSP70, HSP90) in adult myofibroblastic/fibroblastic sarcomas of the extremities by 
immunohistochemistry (IHC).  
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1.3.4.2 Secondary aims 
1. To study the association between the expression of HSPs and the subtype of 
myofibroblastic/fibroblastic sarcoma. 
2. To compare the expression of HSPs between sarcoma and non-metastasising soft tissue 
tumours in general. 
3. To assess the relationship between the expression of these HSPs and the grade of 
sarcomas (high grade vs low grade). 
4. To investigate the relationship between the expression of HSPs with other 











Materials & Methods 
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2  Materials & Methods 
2.1 Patients and tissue samples 
The study was conducted under the Liverpool Musculoskeletal Biobank ethical approval 
(NRES North West Liverpool Central Reference 15/NW/0661) and sponsored by the 
University of Liverpool (reference UoL001223). Informed patient consent for using the 
samples for research purposes was obtained from all patients prior to surgery. 
2.1.1  Patient samples 
Soft tissue samples were obtained from adult soft tissue neoplasms of the extremity resected 
from patients who attended the Northwest Orthopaedic Oncology service in Liverpool from 
2006 to 2016 and who had no history of preoperative radiotherapy or chemotherapy.  
The inclusion criteria for patients were: 
- Adult with soft tissue sarcoma of the extremities 
- Consented  
- No prior treatment with radiotherapy or chemotherapy 
- Detailed clinical information available.  
Detailed clinical pathological parameters (age and sex, tumour site, size, stage, grade and 
distant metastasis) for most of the cases were taken directly from the surgical pathology report 
and patients’ files. The histological diagnosis of soft tissue tumours was made by a specialist 
sarcoma pathologist at Royal Liverpool University Hospital based on World Health 
Organization (WHO) criteria and widely accepted morphological and immunohistochemically 
characteristics. For histological grading, the French Fédération Nationale des Centres de Lutte 
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Contre le Cancer (FNCLCC) system was used. Tumours were classified as upper extremity if 
they were located at, or distal to, the clavicle, lower extremity if they were at, or distal to, the 
pelvic brim. The maximum macroscopic size of the tumour was obtained from the pathology 
report.  
2.1.2 Tissue samples 
All tissue samples were archival paraffin-embedded, formalin-fixed tissue blocks from adult 
soft tissue neoplasms of the extremity resected from patients who attended the Northwest 
Orthopaedic Oncology service in Liverpool from 2006 to 2016, obtained from the Liverpool 
Tissue bank.  
The criteria for tissue selection were:  
1. Availability of informed consent.  
2. Blocks of tissue from the most appropriate region of the tumour by a senior sarcoma 
pathologist consultant: 
o representing tumour cells   
o representing the highest grade in the sample 
o away from necrotic tissue 
o avoid of tumour capsule or reactive tissue 
3. Sufficient tumour tissue present.   
4. Availability of relevant clinical information.   
 
Once the blocks had been selected, sequential 4 μm sections of paraffin block were cut using 
a rotary microtome (Microm, Oxford, UK) from the corresponding formalin-fixed, paraffin-
embedded (FFPE) tissue blocks. 
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2.2  Haematoxylin and eosin (H&E) staining procedure 
One section from each FFPE tissue block was stained with haematoxylin and eosin by the 
Liverpool Tissue Biobank used for histological assessment.  
2.3 Immunohistochemistry (IHC) 
2.3.1 Basics of immunohistochemistry 
Immunohistochemistry (IHC) is a powerful method for localizing specific antigens in formalin-
fixed, paraffin-embedded (FFPE) tissues based on antigen-antibody interaction (198). It is now 
identified as an essential element and an important tool, both in diagnostic and research-
orientated cellular pathology. The technique involves the detection of specific or very selective 
cellular epitopes with an antibody and appropriate labelling system. Immunohistochemistry 
can be performed on cytological compounds, frozen sections and paraffin-embedded 
histological sections (199, 200). The basic steps of an immunohistochemistry protocol are 
detailed in appendix B.   
2.3.1.1 Fixation and section cutting 
The process of fixation is essential for tissue and antigen preservation as it stabilises the 
proteins. The general principle is that the fixatives form cross-links between proteins, thereby 
stabilising the cytoskeletal structure. Formaldehyde (formalin) is the fixative of choice for 
routine histology, therefore, any retrospective studies using patient samples will involve the 
use of immunohistochemistry on formalin-fixed, paraffin-embedded blocks. The aldehydes 
form cross-links between protein molecules, the reaction being with the basic amino acid lysine 
(200, 201). All tissues used in this study are formalin-fixed, paraffin-embedded blocks. 
 
- 71 - 
Generally, unless otherwise specified, sections for IHC were cut at 3 μm, 4 μm or 5 μm. Thicker 
sections may cause difficulty during staining, creating problems in interpretation due to the 
multi-layering of cells. In this study, sequential 4 μm sections of the paraffin block were cut 
using a rotary microtome from the corresponding formalin-fixed, paraffin-embedded (FFPE) 
tissue blocks. This was performed by an experienced technician from the tissue bank at the 
University of Liverpool using a microtome (Microm). The tissues were then placed on labelled 
superior Adhesive Slides (Apex, Leica, UK) and dried overnight in a 37°C oven.  
2.3.1.2 Antigen retrieval (AR) 
Antigen retrieval is the method by which antigens that have been masked through fixation and 
processing, are unmasked prior to immunostaining. There are two main methods for antigen 
retrieval, proteolytic and heat-mediated. Of these two, heat mediated antigen retrieval (HMAR) 
is the most effective on most antigens (201). For this study, HMAR was performed using the 
Dako PT-Link with a high pH. The protocol for PT-Link antigen retrieval is in appendix C.  
The main advantage of HMAR over proteolytic digestion is that heating times to retrieve 
antigens tend to be uniform, regardless of the amount of time spent in fixative. This is in 
contrast to the variability in digestion times required when using enzymes. The main pitfall 
with HMAR is that extreme care must be taken not to allow the sections to dry, as this destroys 
antigenicity (200). 
2.3.1.3 Blocking of endogenous peroxidase 
Peroxidase results in the decomposition of hydrogen peroxide and is a common property of all 
haemoproteins, myoglobin, cytochrome, and catalases. Using the immunohistochemical 
method with one of the reagents labelled with peroxidase requires blocking of the endogenous 
peroxidase present in tissues, which would give a false positive reaction with the applied 
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chromogen (201). In this study, this process was performed by pre-treating sections with Dako 
Envision-Flex block (Dako, UK Ltd.) which exhausts the endogenous enzyme.  
2.3.1.4 Candidate proteins (primary antibodies)  
An antigen can be defined as a molecule (protein, carbohydrate, or lipid) that binds with an 
antibody, and is usually composed of a number of epitopes or antigenic determinant groups. 
An epitope consists of a small amino acid sequence which binds to the variable region of the 
antibody. Due to differences in their manufacture, a monoclonal antibody will only recognise 
one epitope on an antigen, whereas a polyclonal antibody will recognise many epitopes on an 
antigen. The vast majority of primary antibodies available for use on human tissue are made in 
either rabbits or mice. Generally, monoclonal antibodies are preferable to polyclonal 
antibodies, as they tend to be more specific (200).  
In this study, expression of selected heat shock proteins was examined in soft tissue tumours 
using immunohistochemistry. The expression of HSP27, HSP70 & HSP90 was investigated to 
examine their potential role in soft tissue sarcoma and to gain an insight into the pathobiology 
of connective tissue tumours.  
The first antibody is anti-HSP27 primary antibody from Abcam Ltd (UK) is a mouse 
monoclonal (G3.1) to heat shock 27 kDa protein, HSPB1. It reacts with mouse, rat and human 
antigens. Mouse monoclonal IgG1 is suitable for use as an isotype control with this antibody. 
HSPB1 is localised mainly in cytoplasm and detected in many tissues, including gallbladder, 
smooth and skeletal muscles. This antibody was used in immunohistochemistry on human 
tissue in previous research (202, 203). 
The second antibody is anti-HSP70 primary antibody from Abcam, a mouse monoclonal (5A5) 
to heat shock 70 kDa protein 1B, HSPA1B. This antibody recognises human and mouse 
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antigens. Epitope mapping with a panel of HSP70 deletion mutants suggests that the epitope 
recognised is located between amino acids 122–264 of human HSP 70, a region that has been 
shown to be involved in ATP binding. Mouse monoclonal IgG1, is suitable for use as an isotype 
control with this antibody. HSPA1B is testis-specific and localised in the cytoplasm. This 
antibody was used in immunohistochemistry on human tissue in previous research (204, 205). 
The third antibody in this study is anti-HSP90 antibody from Abcam, a mouse monoclonal 
(AC88) to heat shock 84.7 kDa protein, HSP90 alpha and 83.2 kDa protein, HSP90 beta. It 
recognises both HSP alpha and beta in human. The epitope of this antibody has been mapped 
to amino acid residues 604–697 of the human HSP90 sequence. It is localised in the cytoplasm 
and nucleus. This antibody was used in immunohistochemistry on human tissue in previous 
research (206). 
Antibodies for use in immunohistochemistry were optimised by trial runs covering a range of 
concentrations and dilutions (1:100, 1:250 & 1:500) using a PT-link antigen retrieval (AR) 
method. Table 2-1 summarises the primary antibodies of the HSPs used in this study. 
 
Table 2.1 List of HSP primary antibodies used in the study 
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2.3.1.5 Tissue controls used in the study 
Staining control cases were included across experiments to check for the consistency and 
reliability of the immunostaining technique. According to the literature, Human Protein Atlas 
and manufacturer’s recommendations, the positive controls were gallbladder tissue for HSP70, 
skin for HSP27 and testis for HSP90. For negative controls, all staining steps were applied to 
the same positive control tissue except that the mouse non-immune IgG (Dako) was substituted 
in place of the primary mouse antibody at the same dilution as the respective primary antibody. 
Figure 2.1 shows positive and negative tissue controls for various HSPs. 
 
Figure 2.1: Positive and negative tissue controls 
for various HSPs.  
(A) Skin tissue, negative control for HSP27 (1:500), (B) Skin 
tissue (Keratinocytes), positive control for HSP27 (1:500), (C) Gall 
bladder tissue, negative control for HSP70 (1:100), (D) Gall 
bladder tissue (Glandular cells), positive control for HSP70 
(1:100), (E) Testis tissue, negative control for HSP90 (1:500), and 
(F) Testis tissue (Cells in seminiferous ducts), positive control for 
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2.3.1.6 Staining methods 
There is a wide variety of immunohistochemical staining methods available today, but the best 
and most reliable of these are the avidin-biotin and polymer-based systems (200). In this study, 
a polymer-based immunohistochemical method was chosen for the best possible staining.  
Polymer-based methods can be either a two- or three-layer system. In the two-layer system, the 
secondary antibody is part of the polymer molecule and the secondary antibody is conjugated 
to the polymer as a large number of enzyme molecules. The EnVision kit, available from Dako, 
is an example of a two-layer polymer system used in this study (Figure 2.2). In the three-layer 
system, the secondary antibody is applied unconjugated, then the tertiary antibody which is 
conjugated to the polymer along with enzyme molecules. The main advantage of polymer-
based systems is that they can be used on tissues containing a lot of endogenous biotin without 
producing background staining (200). 
 
 
Figure 2.2 The basic immunohistochemistry sequence - a polymer-based method.  
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2.3.1.7 Enzyme labels and chromogens  
Enzymes are the most widely used labels in immunohistochemistry, and incubation with a 
chromogen using a standard histochemical method produces a stable, coloured reaction end-
product suitable for the light microscope. In addition, the variety of enzymes and chromogens 
available allow the user a choice of colour for the reaction end-product. Horseradish peroxidase 
labelling + DAB (3,3′diaminobenzidine tetrahydrochloride) were used in this study and remain 
the most commonly used combination of enzyme and chromogen in immunocytochemistry. 
DAB precipitates to a brown reaction end-product when in the presence of peroxidase and 
hydrogen peroxide (hydrogen peroxide is in solution with the DAB). A by-product of the 
reaction of hydrogen peroxide (the substrate) with peroxidase (the enzyme) is an oxygen 
radical, which acts on DAB and precipitates it at the antigenic site. 
2.3.1.8  Immunostaining procedure using a Dako autostainer 
Immunohistochemistry was performed on 4 µm sections cut from the corresponding formalin-
fixed, paraffin-embedded (FFPE) tissue blocks and the slides were stained on a Dako 
autostainer, an automated slide processing system designed to automate manual staining 
methods routinely used in immunocytochemistry. Briefly, study tissue sections with control 
tissues were run in each assay performed. Slides were labelled with antibody, dilution and date 
using a pencil. Then, slides were placed in the PT-Link (Dako), heated to 96°C, held for 20 
minutes, and returned to 65°C (approx. 1 hour 10 minutes). After that, slides were washed with 
Flex-Wash buffer for 5–15 min and then placed on staining tray. 
Following antigen retrieval, the slides were stained on an autostainer (Dako UK Ltd, Ely, 
Cambridgeshire, UK). Endogenous peroxidases were blocked with a proprietary peroxidase 
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blocking solution (Dako) applied to each section for 10 min. Sections were then washed in Flex 
wash buffer, prior to incubation with the monoclonal primary antibodies for HSP27, HSP70 
and HSP90 (Abcam, UK Ltd) at the appropriate dilution (Table 2.4) for 30 min at room 
temperature. The dilution of the primary antibodies was chosen by testing a range of dilutions 
on positive and negative control sections. Negative control sections were incubated with mouse 
IgG1(Dako, UK Ltd) at the same concentration as the primary antibody. Bound antibody was 
detected using the Dako mouse linker and incubated for 20 min, then, DAB (Dako flex system) 
was added to each slide and incubated at room temperature for 20 min. Finally, the sections 
were counterstained with haematoxylin, dehydrated through the ethanol series and cleared in 
xylene in the fume hood, and mounted with DPX resinous mountant (Merck Chemicals Ltd, 
Nottingham, UK). A trained person supervised the staining procedure to ensure all the steps 
are performed correctly. The slides were examined for the quality of staining by the supervisor. 
The staining was satisfactory and there was no need to repeat any marker. 
2.4 Immunohistochemistry (IHC) analysis and assessment 
2.4.1 Automated quantitative analysis  
Following IHC staining, all slides were scanned digitally using an Aperio Image Scanner. 
Multiple snapshots (digital TIFF images) of the chosen area were captured at x10 
magnification. The number of images varied from 5–10, depending on the size of the selected 
area. Areas of necrotic tumour or those with excess tissue oedema or haemorrhage were avoided. 
In order to eliminate assessment bias, all snapshot images were blinded to the investigator. 
Image analysis was performed using Image J software (version Fiji-wind64). The markers were 
quantified as percentage of area of section stained according to the technique of Hartig et al. 
using image J software (207). This technique relies on choosing the colour deconvolution that 
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eliminates background noise. For colour detection, the colour selection is used to select and 
reserve the positive colour pixels while the background colour pixels are eliminated. After that, 
H DAB vector used to isolate the DAB stain. Staining can be assessed by setting “threshold” 
using the thresholding tool in ImageJ software. Then, the software measures the total DAB 
percentage (positive colour pixels) of section stained area, which is related to the specific 
tissue, based on the antibody used.With my supervisor (Dr Joseph Alsousou), we created a 
macro code (see appendix D) that will automatically perform the colour deconvolution and 
select the brown DAB stain, set the threshold and measure the area fraction and DAB intensity. 
The average of  DAB intensity percentage of stained area for each case was taken When run 
on many slide samples, the results matched the expected manual calculation and visual 
inspection. However, our automated analytic method (ImageJ) did not consider cellularity of 
tumours which might lead to some calculation bias. 
2.4.2 Semi-quantitative scoring 
For the purpose of this study, IHC slides were also analysed semi-quantitatively by two 
observers; an inexperienced investigator (the author) and a pathologist (Dr Susha Varghese). 
They were viewed blind to the clinical and pathological diagnosis. High inter-observer 
agreement was confirmed using Cohen’s Kappa coefficient (k = 0.91, P < 0.001). In case of 
inter-observer differences, consensus was achieved through simultaneous reassessment of the 
respective specimen by both investigators. 
At least five fields were used to evaluate expression of HSPs for each case under a standard 
light microscope (x400) or digital image(40x). Then, a semi-quantitative estimate was made 
using a immunoreactive score (IRS) as described by Remmele et al.,1987 (208).  Expression 
of HSPs was assessed by determination of IHC staining based on the intensity of 
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immunostaining and the percentage of stained tumour cells. Immunostaining was scored as 0 
(no immunostaining), 1 (weak immunostaining), 2 (moderate immunostaining), or 3 (strong 
immunostaining). The percentage of positive tumour cells was scored as 0 (none), 1 (< 10%), 
2 (10–50%), 3 (51–80%), or 4 (> 80%). Multiplication of the scores for intensity and 
percentage resulted in the immunoreactive score (IRS) ranging from 0 to 12 (Table 2-2). For 
the statistical analysis, expression of HSPs was dichotomised into either low expression (score 
0–3), or high expression (score 4–12). Similar method of analysis for IHC staining of HSPs 
was used in many previous cancer studies including breast and colon cancers  (209-211). 
Table 2.2 Immunoreactive score (IRS) according to Remmele and Stegner, 1987 (208) 
A (Percentage of positive cells) B (Intensity of staining)  IRS score (multiplication of A and 
B) 
0 = no positive cells 0 = no colour 0-1 = negative 
1 = < 10% of positive cells  1 = mild reaction 2-3 = weak 
2 = 10-50% positive cells 2 = moderate reaction 4-8 = moderate 
3 = 50-80% positive cells 3 = intense reaction 9-12 = strong 
4 = > 80% positive cells   
 
2.4.3  Relationship between automated quantitative analysis and semi-
quantitative scoring 
The relationship between automated quantitative analysis (% of staining area) and semi-
quantitative scoring (IRS scoring) was investigated using Spearman’s rank order correlation. 
There was a positive correlation between the two variables (p < 0.05), with high levels of 
automated % staining area associated with higher IRS. 
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2.5 Clinical follow-up 
Patients had follow-up appointments every 3 months for the first 3 years after surgery, every 6 
months for the next 2 years, and yearly thereafter. The presence or absence of recurrence was 
confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) every 12 
months after surgery. Follow-up was calculated from the day of primary surgery and overall 
survival (OS) was calculated from the date of surgery to the date of death. 
2.6 Statistical analysis 
Statistical analyses were performed using the software package SPSS, version 22.0 (SPSS, 
Chicago, IL), at the University of Liverpool with the advice and assistance of my supervisors. 
In all statistical analyses, the initial step was to assess whether the data were normally 
distributed. This is performed automatically by SPSS, which superimposes a normal curve on 
the data histogram and using Shapiro Wilk’s test. Wherever there was uncertainty or two data 
sets were to be compared in which there were both normally and non-normally distributed data, 
non-parametric statistics were used. This means that the analyses might be less sensitive than 
had it been possible to apply parametric statistics, but this was considered an advantage as it 
decreased the likelihood of obtaining false positive relationships between biomarker 
expression and biological/clinical significance. All data were recorded onto datasheets in 
Microsoft Office Excel Software and then transferred to the SPSS (Statistical Package for 
Social Sciences) version 22. Different tests were used for different aspects of the analysis as 
these analyses were better applied to each data set/ combination of data sets. Thus:  
▪ Parametric data were described as means +/- standard deviation, whilst non-
parametric data were reported as median with ranges. With regards to 
categorical data, they were presented in number & percentages.  
▪ Categorical data were compared by chi-square or Fisher’s exact tests. 
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▪ The Mann-Whitney U test was used to test for differences between two 
independent groups on a continuous measure. 
▪ The Kruskal Wallis test was used to test for differences between more than two 
independent groups on continuous variables. 
▪ The Spearman’s rank order test was used to test correlation between two non-
parametric continuous variables. 
▪ OS was calculated using the Kaplan-Meier method. Death from disease was 
taken as the endpoint for disease-specific survival, patients dying from other 
causes were censored at the date of death.  














3.1 Normality test for continuous variables 
This study had categorical, ordinal and continuous variables, requiring different statistical 
analysis for the different type of variables. For continuous variables, it is important to assess if 
data is normally distributed (parametric) or not (non-parametric), because different statistical 
tests are used for parametric and non-parametric data. The Shapiro-Wilk statistical test was 
used to assess the normality of the distribution of the continuous data. In this study, a P value 
less than 0.05 was considered significant, which suggests violation of the assumption of 
normality (Table 3-1). Hence, non-parametric tests were used for continuous variables.  
Table 3.1 Normality tests for continuous variables 
  Shapiro-Wilk 
Statistic df Sig. 
Age (year) 0.922 43 0.006 
Size of tumour (mm) 0.916 43 0.004 
HSP27 staining 0.912 43 0.003 
HSP70 staining 0.933 43 0.015 




3.2 Clinical and pathological characteristics of patients and tumour types 
This study included 43 patients with myofibroblastic/fibroblastic tumours of the extremities, 
35 patients (81.4%) had sarcoma tumours, and only eight patients (18.4%) had non-
metastasising tumours. The subtypes of tumours were myxofibrosarcomas (n = 26), 
myofibroblastic sarcomas (n = 3), fibromyxoid sarcomas (n = 3), myxoinflammatory 




Figure 3.1 Number of cases for each type of tumour 
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3.2.1 Clinicopathological parameters of soft tissue sarcomas 
There were 35 myofibroblastic/fibroblastic sarcomas included in this study, 17 (48.6%) were 
men, and 18 (51.4%) were women. The median age of patients with sarcomas was 70.0 years 
at diagnosis (range 27–94 years). The median maximum diameter of a tumour was 81.1 mm 
(range 35–150 mm). Tumours were histologically FNCLCC grade I in 7 (20%), grade II in 5 
(14.3%) and grade III in 24 (68.7%). The tumour was located in the upper limb in 11 patients 
(31.4%) and the lower limb in 24 (68.5%) patients. A total of 8 patients (22.8%) developed 
metastatic disease, of which, 7 had FNCLCC grade III at presentation and one patient had a 
grade II tumour. Three patients had metastasis at the time of diagnosis. Metastases were in the 
lung in seven patients and groin lymph node in one. Table 3.2 summaries clinicopathological 
features for patients with STSs.  
Table 3.2 Clinical and pathological characteristics for patients with sarcomas. 










Gender Male 11 1 3 2 17 (48.6) 
Female 15 2 0 1 18 (51.4) 
Age 
(years) 
Median 69.0 81.0 75.0 59.0 70.0 
Range 27-94 80-83 68-82 54-68 27–94 
Site  Upper Limb 6 1 2 2 11 (31.4) 
Lower Limb 20 2 1 1 24 (68.6) 
Size  
(mm)  
Median 84.0 72.0 80.0 61.0 81.0 
Range 35-150 58-100 50-100 55-65 35–150 
Grade Low Grade 3 1 0 2  7 (20) 
Intermediate 
Grade 
3 0 1 1  5 (14.3) 
High Grade 20 2 2 0  24 (68.7) 
Metastasis No Metastasis 19 3 2 3 24 (88.6) 
Metastasis 7 0 1 0 8 (11.4) 
Number (%), MFS (myxofibrosarcoma), MS (myofibroblastic sarcoma), MIFS (myxoinflammatory fibroblastic 
sarcoma), FS (fibromyxoid sarcoma). 
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3.2.2 Clinicopathological parameters of Non-metastasising Tumors 
There were eight non-metastasising myofibroblastic/fibroblastic tumours included in this 
study, four (50%) males and four (50%) females. The median age of patients was 41.8 years at 
diagnosis (range 24–65 years). These tumours had a median size of 50.6 mm (range 40-58mm), 
six tumours (75%) were in the lower limb and two (25%) were in the upper limb extremity.  
Table 3.3 summaries clinicopathological features for patients with non-metastasising tumours.  
Table 3.3 Clinical and pathological characteristics for patients with non-metastasising tumours 






Gender Male 3 1 4 (50) 
Female 0 4 4 (50) 
Age  
(years) 
Median 60.6 54.33 41.8 
Range 58-65 50-58 24-65 
Site  
(mm) 
Upper Limb 0 2 2 (25) 
Lower Limb 3 3 6 (75) 
Size  Median 30.6 3 50.6 






3.2.3 Comparison between myofibroblastic/fibroblastic sarcomas and their non-
metastasising counterparts  
Comparison of clinicopathological features between myofibroblastic/fibroblastic sarcomas  
and their non-metastasising counterparts are summarised in table 3-4.   
Table 3.4 Clinicopathological comparison between myofibroblastic/fibroblastic sarcomas and their 
non-metastasising counterparts 








  (n=35) (n=8) 
Gender          0.94 
  Male  21 17 4   
Female  22 18 4   
Age (years)          0.001* 
  Median   74.0 36.8   
Range   27-94 24-65   
Site          0.72 
  Upper Limb  13 11 2   
Lower Limb  30 24 6   
Size (mm)         0.002* 
  Median   80.0 50.0   
Range   25-150 40-58   
Number (%). Statistical analysis based on Fisher’s exact test for categorical variables, Mann-Whitney test for 
continuous variables, p < 0.05 indicates a significant association. 
Fisher’s exact test revealed that there was no statistical significance difference (p = 0.94) in 
gender between myofibroblastic /fibroblastic sarcomas (male = 17, female = 18) and non-
metastasising tumours (male = 4, female = 4). Furthermore, there was also no statistically 
 
88 
significant (p = 0.72) association between the tumour site and type of tumour soft tissue 
sarcoma tumours (upper limb =11, lower limb = 24) and non-metastasising tumours (upper 
limb = 2, lower limb = 6). 
However, a Mann-Whitney U test revealed a significant difference (U = 31.000, Z = -3.403, p 
= 0.001) in the age of sarcoma patients (median = 74, n = 35) and  patients with non-
metastasising tumours (median = 36, n = 8). The effect size (r value) is 0.5, and this would be 
considered a strong effect size according to Cohen’s criteria (212). Myofibroblastic/fibroblastic 
sarcoma had a higher median age of patients (median = 74) than non-metastasising tumours 
(median = 36).  Similarly, a Mann-Whitney U test revealed a statistical significant difference 
(U = 41.000, Z = -3.098, p = 0.001) in the size of sarcoma patients (median = 80, n = 35) and 
patients with non-metastasising tumours (median = 50, n=8). The r value is 0.4 and considered 
a medium effect size. Soft tissue sarcoma tumours had a higher median size (median = 80) than 
non-metastasising tumours (median = 50). Figure 3.2 illustrates comparison of patient age and 






Figure 3.2 Comparison of patient age and tumour size between myofibroblastic/fibroblastic sarcoma 
and their non-metastasising counterparts’ tumours. Sarcoma patients had a higher median age and a 
higher median tumour size than non-metastasising tumours (p<0.05).
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3.3 Overview of IHC staining of HSPs in neoplastic and non-neoplastic cells 
IHC staining of HSPs were demonstrated in non-neoplastic and neoplastic cells. The 
distribution and amount of stain in non-neoplastic cells are detailed in Table 3-5. The staining 
patterns of malignant cells are the subject of this section of the thesis.  In terms of analysis, the 
vast majority of cells present in tumour tissue were neoplastic cells, other cells present in low 
numbers were macrophages and endothelial cells.  
Immunoreactive staining of anti-HSP27 was detected mainly in the cytoplasm of tumour cells. 
However, IHC staining for anti-HSP27 was positive in non-neoplastic cells such as endothelial 
cells, inflammatory cells and fibroblasts. Furthermore, it was found that HSP27 was expressed 
in the extracellular matrix. Figure 3.3 shows an example of HSP27 staining in 
myxofibrosarcoma.  
IHC staining of anti-HSP70 was found in both the nucleus and cytoplasm of tumour cells. 
Although HSP70 staining is negative in most non-neoplastic cells, such as endothelial cells and 
inflammatory cells, it does show some trace staining in the extracellular matrix. Figure 3.4 
shows an example of IHC staining of anti-HSP70 in myxofibrosarcoma and demonstrates the 
pattern of staining in neoplastic and non-neoplastic cells. 
Similarly, IHC staining of HSP90 was detected in both nucleus and cytoplasm of tumour cells. 
However, endothelial and inflammatory cells were also positive for HSP90 staining. 
Nevertheless, it was almost negative in the extracellular matrix. Figure 3.5 shows an example 
of IHC staining of HSP90 in myxofibrosarcoma and demonstrates the pattern of staining in 












Figure 3.3 Example of IHC staining of HSP27 in myxofibrosarcoma showing the pattern of staining 
in neoplastic and non-neoplastic cells. Different magnifications, x2, x4, x10 and x40. IHC staining 
of anti-HSP27 was detected mainly in the cytoplasm of tumour cells. However, IHC staining for anti-







Figure 3.4 Example of IHC staining of HSP70 in myxofibrosarcoma showing the pattern of staining in 
neoplastic and non-neoplastic cells. Different magnifications, x2, x4, x10 and x40. IHC staining of anti-
HSP70 was found in both the nucleus and cytoplasm of tumour cells. However, HSP70 staining is 







Figure 3.5 Example of IHC staining of HSP90 in myxofibrosarcoma showing the pattern of staining 
in neoplastic and non-neoplastic cells. Different magnifications, x2, x4, x10 and x40. IHC staining 
of HSP90 was detected in both nucleus and cytoplasm of tumour cells. However, endothelial and 
inflammatory cells were also positive for HSP90 staining 
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3.4 HSP27 expression  
3.4.1 Expression of HSP27 in different tumour types 
IHC staining of anti-HSP27 was positive in all tumour types included in this study. However, 
a Kruskal-Wallis Test revealed that there is no significant statistical difference in HSP27 
expression across the tumour subtypes (Chi-Square = 6.05, df = 5, P = 0.2). Table 3-6 
summarises staining of HSP27 in various type of tumours and figure 3.7 shows an example of 
the HSP27 staining in various type of the tumours.  
Table 3.5 Summary of HSP27 staining in different type of tumours 
  HSP27 Staining (%)* 
Median Range Mean SD 
Myxofibrosarcoma (n=26) 28.09 1.09-93.42 29.76 20.96 
Myofibroblastic sarcoma (n=3) 78.34 31.61-85.31 65.09 29.20 
Myxoinflammatory fibroblastic 
sarcoma (n=3) 
47.38 1.89-94.30 47.86 46.21 
Fibromyxoid sarcoma (n=3) 39.47 12.13-51.27 34.29 20.08 
Myxoma (n=3) 14.91 12.18-26.54 17.88 7.63 
Fibromatosis (n=5) 21.09 0.67-42.81 19.83 18.52 







Figure 3.3 Examples of expression of HSP27 in different tumour types. Magnification scale: 300 µm. 
A) HSP27 expression in Myxofibrosarcoma. B) HSP27 expression in Myofibroblastic sarcoma. C) HSP27 
expression in MIFS. D) HSP27 expression in Fibromyxoid sarcoma. E) HSP27 expression in Myxoma. F)  






3.4.2 Comparison of HSP27 expression between STS tumours and non-
metastasising tumours 
Overall expression of HSP27 in soft tissue sarcoma (median = 31.61, n = 35) was higher than 
in non-metastasising tumours (median = 18.00, n = 8). However, there is no statistically 
significantly difference in HSP27 expression between two groups using a Mann-Whitney U 
Test (Z = - 1.67, p = 0.9).  
 
Figure 3.4 Comparison of HSP27 staining between STS tumours and non-metastasising tumours. There 





3.4.3 Relationship between HSP27 expression and the grade of STSs 
The relationship between HSP27 expression and grade of STSs was investigated using 
Spearman’s rank order correlation. Although, high levels of HSP27 were associated with a 
higher grade of soft tissue sarcoma, this was not statistically significant (rs = 0.29, p = 0.08). 
Figure 3.10 demonstrates an example of HSP27 expression in different grade of STSs. 
 







Figure 3.6 HSP27 expression in different grade of Myxofibrosarcoma.  







3.4.4 Relationship between HSP27 expression and clinicopathological features 
Table 3-7 illustrates the relationship between the percentage of HSP27 expression and clinical 
features of soft tissue tumours included in this study. 
Table 3.6 Relationship between HSP27 expression and clinicopathological features of tumours 
  HSP27 staining (%) 
 




31.61 1.09 94.30 30.41 21.25 
Female (n=22) 
 
24.79 .67 93.42 33.16 27.31 
Upper Limb (n=13) 
 
39.47 .67 93.42 35.86 25.61 
Lower Limb (n=30) 
 
26.56 1.09 94.30 30.07 23.93 
No Metastasis (n=4) 
 
29.09 .67 93.42 30.06 22.58 
Metastasis (n=39) 
 
44.82 11.78 94.30 48.93 36.98 
*% of area of section stained using automated analysis 
The relationship between HSP27 expression and the age of patients was investigated using 
Spearman’s rank order correlation. There was no statistically significant correlation between 
the two parameters (rs = 0.17, p = 0.2). Also, Spearman’s test showed that there was no 
statistically significant correlation between HSP27 expression and the size of a tumour (rs = - 
0.029, p = 0.8). 
A Mann-Whitney U Test revealed no significant difference (z = -.17, p = 0.8) in the HSP27 
expression of males (median = 31.61, n = 21) and females (median = 24.79, n = 22). Also, a 
Mann-Whitney U Test revealed no significant difference (z = -.95, p = 0.3) in the HSP27 
expression between upper limb tumours (median = 39.47, n = 13) and lower limb tumours 
(median = 26.56, n = 30).  
Although median percentage of HSP27 expression metastatic group was higher than the non-
metastatic group, a Mann-Whitney U Test revealed that there was no significant difference (z 
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= -.96, p = 0.4) in the HSP27 expression between non-metastatic patients (median = 29.09, n 
= 31) and metastatic patients (median = 44.82, n = 4). 
 
 
Figure 3.7 Relationship between HSP27 expression (% of staining area) and clinical features (patient 




3.5 HSP70 expression 
3.5.1 Expression of HSP70 in different tumour types 
Table 3-8 summarises staining of HSP70 in various type of tumours. A Kruskal-Wallis Test 
revealed that there was a significant statistical difference in HSP70 expression across six 
tumour subtypes included in this study (Chi-Square = 11.4, df = 5, p = 0.044). 
Myxofibrosarcoma tumours had a higher median HSP70 expression (median = 19.22) than the 
other groups. Pairwise comparisons were executed using Dunn’s procedure with a Bonferroni 
correction for multiple comparisons. Values were derived from mean ranks unless specified 
otherwise and adjusted p-values were reviewed. The post hoc analysis revealed a statistically 
significant difference (p= 0.006) between the myxofibrosarcoma group (median = 19.22) and 
myxoma group (median = 3.86). However, no significant difference was found between other 
types of tumours. 
Table 3.7 HSP70 expression in different tumour types 
 
HSP70 staining (%) 
Median Minimum Maximum Mean SD 
Myxofibrosarcoma (n=26) 19.22 .22 54.26 20.86 12.36 
Myofibroblastic sarcoma 
(n=3) 
11.90 10.26 21.56 14.57 6.11 
Myxoinflammatory 
fibroblastic sarcoma (n=3) 
12.30 11.57 32.42 18.76 11.83 
Fibromyxoid sarcoma 
(n=3) 
5.66 5.21 19.77 10.21 8.28 
Myxoma (n=3) 3.86 2.46 5.38 3.90 1.46 
Fibromatosis (n=5) 6.46 2.09 24.46 10.05 8.63 





Figure 3.8 Examples of IHC staining of HSP70 in different type of tumours.  
A) HSP70 expression in myxofibrosarcoma, B) HSP70 expression in myofibroblastic sarcoma, C) HSP70 
expression in myxoinflammatory fibroblastic sarcoma, D) HSP70 expression in fibromyxoid sarcoma, E) 






3.5.2 Relationship between HSP70 expression and grade of STSs 
The relationship between HSP70 expression and grade of STSs was investigated using 
Spearman’s rank order correlation. There was a medium, positive correlation between the two 
variables (rs = 0.33, p = 0.02), with high levels of HSP70 associated with a higher grade of soft 
tissue sarcoma (Figure 3.10). An example of HSP70 expression in a different grade is 
demonstrated in figure 3-11. 
 
 
Figure 3.9 Relationship between HSP70 staining and the grade of STS. There was a positive correlation 





Figure 3.10 HSP70 expression in different grade of Myxofibrosarcoma.  






3.5.3 Comparison of HSP70 expression between STSs and non-metastasising 
tumours 
Soft tissue sarcoma tumours have a higher median expression of HSP70 (median = 16.50) than 
non-metastasising soft tissue tumours (median = 5.90). A Mann-Whitney U Test revealed that 
there was a statistical significant difference (U = 52.00, z = -2.746, p = 0.005) in the expression 
of HSP70 between STS tumours (median = 16.50, n = 35) and non-metastasising soft tissue 
tumours (median = 5.90, n = 8). The r value was 0.4, a medium effect size using Cohen’s 
criteria. Figure 3.12 illustrates the comparison of HSP70 expression between STSs and non-
metastasising tumours.  
 
Figure 3.11 Comparison of HSP70 staining between STS tumours and non-metastasising tumours. 
There was a statistically significant difference in HSP70 expression between two groups.  
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3.5.4 Relationship between HSP70 expression and clinicopathological features 
Table 3-9 illustrates the relationship between the percentage of HSP70 staining and 
clinicopathological features of soft tissue tumours included in this study. 
Table 3.8 Relationship between HSP70 expression and clinicopathological features of tumours 
  HSP70 staining (%) 
Median Minimum Maximum Mean Standard 
Deviation 
Male (n=21) 13.49 2.46 34.69 15.69 10.05 
Female (n=22) 16.69 .22 54.26 18.43 13.49 
Upper Limb (n=13) 14.08 5.21 54.26 18.68 13.20 
Lower Limb (n=30) 14.22 .22 39.34 16.40 11.42 
No Metastasis 
(n=39) 
14.31 .22 54.26 17.46 12.37 
Metastasis (n=4) 13.22 8.99 18.41 13.46 3.93 
*% of area of section stained using automated analysis 
The relationship between HSP70 expression and the age of patients was investigated using 
Spearman’s rank order correlation. There was no statistically significant correlation between 
the two parameters (rs = 0.13, p = 0.39). Furthermore, a Mann-Whitney U Test revealed no 
statistical significant difference (z = -.65, p = 0.51) in the HSP70 expression of males (median 
= 13.49, n = 21) and females (median = 16.69, n = 22). In addition, there was no statistical 
significant difference (z = -0.39, p = 0.7) in the HSP70 expression between upper limb tumours 
(median = 14.08, n = 13) and lower limb tumours (median = 14.22, n = 30).  
The relationship between HSP70 expression and the size of tumours was investigated using 
Spearman’s rank order correlation. There was no statistically significant correlation between 
the two variables (rs = 0.218, p = 0.16). 
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A Mann-Whitney U Test revealed no significant difference (z = -.37, p = 0.73, r =0.05) in the 
HSP70 expression between non-metastatic patients (median = 14.31, n = 39) and metastatic 
patients (median = 13.22, n = 4).  
 
Figure 3.12 Relationship between HSP70 expression (% of staining area) and clinical features (patient 
age, size of tumour, gender, tumour site and metastasis). Not significant statistically.  
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3.6 HSP90 Expression 
3.6.1 Expression of HSP90 in different tumour subtypes 
Table 3.10 summarises expression of HSP90 in various type of tumours. A Kruskal-Wallis 
Test revealed that there is no significant statistical difference in HSP90 expression across six 
tumour subtypes included in this study (Chi-Square = 2.85, df = 5, p = 0.72). An example of 
IHC staining of HSP90 in different type of tumours is demonstrated in figure 3.14. 
Table 3.9 Expression of HSP90 in different tumour subtypes 
  HSP90 staining (%) 
Median Minimum Maximum Mean Standard Deviation 
Myxofibrosarcoma 
(n=26) 
1.59 .12 51.57 6.33 11.37 
Myofibroblastic 
sarcoma (n=3) 




1.12 .58 10.96 4.22 5.84 
Fibromyxoid 
sarcoma (n=3) 
.18 .17 2.95 1.10 1.60 
Myxoma (n=3) 2.48 .11 9.24 3.94 4.74 
Fibromatosis (n=5) .38 .13 25.31 5.42 11.12 





Figure 3.13 Examples of IHC staining of HSP90 in different type of tumours.  
A) HSP70 expression in myxofibrosarcoma, B) HSP90 expression in myofibroblastic sarcoma, C) HSP90 
expression in myxoinflmmatory fibroblastic sarcoma, D) HSP90 expression in fibromyxoid sarcoma, E) HSP90 






3.6.2 Relationship between HSP90 expression and grade of STSs 
The relationship between HSP90 expression and grade of STSs was investigated using 
Spearman’s rank order correlation, with no significant correlation between the two variables 
(rs = 0.14, p = 0.34). Figure 3.15 illustrates the relationship between HSP90 expression and the 
grade of STSs. 
 
 




3.6.3 Comparison of HSP90 expression between STSs and non-metastasising 
tumours 
A Mann-Whitney U Test revealed that there is no statistical significant difference (U = 118.00, 
z = -0.687, p = 0.51, r = 0.1) in the expression of HSP70 between STS tumours (median = 1.61, 
n = 35) and non-metastasising soft tissue tumours (median = 0.75, n = 8). Figure 3.16 illustrates 
the comparison of HSP90 expression between STSs and non-metastasising tumours.  
 
 
Figure 3.15 Comparison of HSP90 staining between STS tumours and non-metastasising tumours. 
There was no significant difference between two groups.  
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3.6.4 Relationship between HSP90 expression and clinicopathological features 
Table 3.11 illustrates the relationship between the percentage of HSP70 staining and 
clinicopathological features of soft tissue tumours included in this study. A Mann-Whitney U 
Test detected no significant difference (U = 179.00, z = -1.26, p = 0.2) in the HSP90 expression 
of males (median = 0.58, n = 21) compared to females (median = 2.36, n = 22). 
 
Table 3.10 Relationship between HSP90 expression and clinicopathological features 
  HSP90 staining (%) 
Median Minimum Maximum Mean Standard 
Deviation 
Male (n=21) .58 .11 51.57 5.40 11.69 
Female (n=22) 2.36 .12 25.82 6.04 7.93 
Upper Limb 
(n=13) 
1.12 .13 51.57 8.76 15.02 
Lower Limb 
(n=30) 
1.59 .11 25.82 4.41 6.38 
No Metastasis 
(n=39) 
1.12 .11 51.57 5.66 10.20 
Metastasis (n=4) 6.23 1.24 11.74 6.36 5.77 
*% of area of section stained using automated analysis 
Also, the relationship between HSP90 expression and the age of patients was investigated using 
Spearman’s rank order correlation, with no statistically significant correlation between the two 
parameters (rs = 0.06, p = 0.69). Similarly, there was no statistically significant correlation (rs 
= -0.18, p = 0.22) between HSP90 expression and the size of tumours. 
A Mann-Whitney U Test revealed no statistical significant difference (z = -0.71, p = 0.48) in 
the HSP90 expression between upper limb tumours (median = 1.12, n = 13) and lower limb 
tumours (median = 1.59, n=30). Likewise, there was no significant difference (U = 50.00, z = 
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-1.17, p = 0.26) in the HSP90 expression between the non-metastatic patient group (median = 
1.12, n = 39) and metastatic patient group (median = 6.23, n=4).  
 
 
Figure 3.16 Relationship between HSP90 expression (% of staining area) and clinicopathological 








3.7 Correlations between the expression of heat shock proteins 
The relationship between HSP27 expression and HSP70 expression was investigated using 
Spearman’s rank order correlation. There was a medium, positive correlation between the two 
variables (rs = 0.43, p = 0.004), with high levels of HSP27 associated with higher levels of 
HSP70. On the other hand, there was no significant correlation between HSP27 expression and 
HSP90 expression (rs = 0.69, p = 0.65), or between HSP70 expression and HSP90 expression 
(rs = 0.16, p = 0.3). Figure 3.18 shows the correlations between the expression of the heat shock 
proteins. 
  
Figure 3.17 Correlations between the expression of the heat shock proteins. There was only a positive 
correlation between HSP27 expression and HSP70 expression.  
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3.8 Survival analysis 
Overall survival in the 35 cases of soft tissue sarcomas ranged from 2 to 120 months. Patients 
were classified as alive (n = 24), dead (n = 8), or lost to follow-up (n = 3). The Kaplan-Meier 
method (the log-rank test) was used for analysis of survival, revealing no significant association 
between survival and HSP27, HSP70, or HSP90 expressions. However, there was only a 
significant relationship between metastasis and survival (p = 0.001). Analysis of all 
clinicopathological variables for overall survival in STS patients is illustrated in table 3.12. 
Table 3.11 Analysis of all clinicopathological variables for overall survival in STS patients 
























Soft tissue sarcomas are a rare and a heterogeneous group of malignancies that originate from 
mesenchymal tissue. Their rarity, coupled with their variety, is challenging for investigators to 
understand their natural history, prognosis and management. Soft tissue sarcoma tumours are 
well known for their aggressiveness and resistance to anticancer therapy. 
The heat shock proteins (HSP) constitute a superfamily of chaperone proteins present in all 
cells and in all cell compartments, operating in a complex interplay with a 
synergistic/overlapping multiplicity of functions, even though the common effect is cell 
protection and cell survival. Several reasons explain the need for investigating HSPs in STSs: 
(1) these molecules function as chaperones of tumorigenesis, (2) they are associated with 
disease aggressiveness and with resistance to anticancer therapies including radiotherapy and 
chemotherapy, and (3) they can be used as targets for therapies. 
However, only limited work has been conducted on the role of HSPs in connective tissue 
tumours, so much of the current knowledge about HSPs relates to carcinomas rather than 
sarcomas. The work presented in this thesis is based on the hypothesis that similar mechanisms 
of HSPs may be involved in tumorigenesis and aggressiveness in sarcomas as in carcinomas. 
Hence, the present study was performed to clarify the expression of those HSPs in soft tissue 
sarcomas. This work focused on the expression of HSP27, HSP70 and HSP90 in 
myofibroblastic/fibroblastic sarcoma (STS) of extremities, with a final goal to provide further 
insight on the biological behaviours of STS by focusing on the correlations between the 
expression of each protein and clinicopathological parameters. To the best of our knowledge, 
this is the first study to investigate the three selected HSPs (HSP27, HSP70 and HSP90) in 
adult myofibroblastic/fibroblastic sarcomas of extremities. 
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Due to the rarity of sarcomas, the present study focused on archived tissue to obtain sufficient 
material for the study. The material was formalin-fixed and paraffin embedded, and there was 
limited clinical and pathological data available. These constraints limited the techniques that 
could be employed to examine the expression of the chosen biomarkers, to 
immunohistochemistry (IHC) and in situ hybridization. Immunohistochemistry was chosen 
because by studying the expression of protein, one of the unknowns in investigating HSPs, 
translation of mRNA into protein, was eliminated.  
Although the majority of results were not clear cut, a number of significant findings did emerge 
from the present study. In view of the fact that there is a lack of similar data on STS, it was 
considered appropriate for a discussion of the study findings and comparison of the results to 
other types of tumours in the literature. 
4.1 Discussion of the study findings and those described in the literature 
Surrogates were used to assess the importance of HSP expression and regulation to tumour 
behaviour in the absence of any specific markers.  Of particular interest, was the relationship 
of expression of HSPs to histological grading, which is the best indicator of the aggressiveness 
of those tumours to date. In addition, tumours of different levels of malignancy (from benign 
to highly aggressive) were compared to identify patterns of biomarker expression that most 
clearly related to tumorigenesis. A total of 43 tumours were available for this study as archival 
formalin-fixed, paraffin-embedded tissue blocks.  
4.1.1 Clinicopathological Parameters  
With regard to clinicopathological features of sarcoma tumours and non-metastasising 
tumours, this study showed that patient age and size of tumour were statistically significantly 
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different between these two groups (p = 0001), as malignant tumours occurred in older patients 
and had a larger size than non-metastasising tumours. Overall, the incidence of soft-tissue 
sarcomas increases significantly with age, with more than 65% of cases occurring in patients 
aged 50 and over (5). Furthermore, there was a significant correlation between the size of tumour 
and grade of soft tissue sarcoma; a large tumour size associated with a higher grade of soft tissue 
sarcoma (p = 0.04). Similarly, a study by Stojadinovic et al. showed that a large tumour size was 
consistently associated with a higher grade and a poor prognosis of STS (39). 
4.1.2 Expression of HSP27  
In this study, the staining of HSP27 was positive in all types of soft tissue tumours. Although 
HSP27 was more highly expressed in sarcoma tumours, particularly myofibroblastic sarcoma 
and MIFS compared to non-metastasising tumours, there was no significant statistical 
difference in expression between the non-metastasising and sarcoma tumours. Similarly, there 
was a trend for high HSP27 expression in high-grade STSs and metastatic group; however, this 
was not statistically significant. Furthermore, there were no statistically significant differences 
in relation to age, gender, tumour size, tumour site and survival outcome.  
In the oncology field, many studies have found that HSP27 was overexpressed in a wide range 
of malignant cells and tissue compared to normal tissue. For example, Wataba et al. in an IHC 
study found that HSP27 was overexpressed in hyperplastic endometrium and carcinoma 
compared to normal endometrium tissue (213). Also, in a study of biopsy samples from prostate 
cancer patients, expression of intracellular HSP27 expression in prostate cancer tissue was up-
regulated compared to the controls (214). Rui et al. also demonstrated that HSP27 levels in 
serum were significantly higher in breast cancer patients compared to healthy controls (215). 
Similarly, Grzegrzolka et al. found that HSP27 expression was significantly higher in 101 
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patients with invasive ductal breast carcinoma compared to 20 patients with benign fibrocystic 
lesions (209).  
Many studies have investigated the correlation of HSP27 expression with grade and poor 
survival in many cancer tissues. For instance, King et al. examined expression of HSP27 in 58 
patients with hepatocellular cancer and adjacent non-cancerous liver tissue by IHC, finding a 
significantly higher distribution of HSP-27 expression in HCC tissues compared with adjacent 
non-cancerous liver tissues and that HSP-27 expression was positively correlated with a 
histologic tumour grade and poor survival rate (216). HSP27 expression was also strongly 
correlated with poor survival in patients with rectal tumours (217). Assimakopoulou et al. 
reported that HSP27 expression was correlated with histological grades of astrocytoma (218). 
Similarly, Moon et al. found that significantly high levels of HSP27 expression in conventional 
osteosarcoma compared to low-grade osteosarcoma and it was significantly related to distant 
metastasis with a tendency toward poor survival (219). Recently, Shuangjiang et al. found in 
their meta-analysis that high HSP27 expression can be an effective biomarker for predicting 
poor clinicopathological parameters of non-small cell lung cancer, including the degree of 
differentiation, lymphatic metastasis, TNM stage, histological subtypes and tumour size (220). 
In contrast, HSP27 expression has been associated with good prognosis in endometrial 
adenocarcinomas, oesophageal cancer, and in malignant fibrous histiocytomas. Muzio et al. 
analysed 79 cases of oral squamous cell carcinoma and 10 cases of normal mucosa for HSP27 
expression by IHC. They found that patients with reduced HSP27 expression had more 
aggressive (higher grade and poorly differentiated) carcinoma, with a poor survival rate (221). 
In malignant fibrous histiocytoma, Tetu et al. (1992) evaluated by IHC the prognostic influence 
of the expression of HSP27 in 43 malignant fibrous histiocytomas, finding that HSP-27 
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expression was associated with a more favourable prognosis, and a significant correlation was 
observed with overall survival and metastasis-free survival (222). 
Taken together, these results suggest that HSP27 plays a role in tumorigenesis and is a marker 
of aggressiveness of STSs, but not useful in diagnostic immunopathology. However, further 
experimentation is needed to investigate the biological functions of HSP27 proteins, that is, 
potential pleiotropic function in soft tissue sarcoma.  
4.1.3 Expression of HSP70  
In broad terms, this study showed that HSP70 expression was higher in 
myofibroblastic/fibroblastic sarcomas than the non-metastasising counterpart. Unlike HSP27, 
there was a significant statistical difference in the expression of HSP70 between sarcomas and 
non-metastasising tumours (p < 0.05). Similar to HSP27, there was a positive correlation 
between expression of HSP70 and the grade of STSs, with high levels of HSP70 associated 
with a higher grade of STSs. However, there was no significant relationship between HSP70 
expression and patient age, gender, tumour location, tumour size, metastasis and survival. 
There is extensive evidence in the literature that HSP70 is overexpressed in many cancers, and 
that high expression of this chaperone correlates with increased tumour grade and poor 
prognosis. A comparative pilot study of protein profiles of human hepatocellular carcinoma 
and non-tumour human liver samples showed that HSP70 is over expressed (2 fold) in the 
tumour cells compared to the non-tumor tissue (223). Isomoto et al. demonstrated that there is 
a significant correlation between HSP70 and HSP40 expression and histopathological typing 
of gastric cancer and concluded that these HSPs are less frequently expressed in 
undifferentiated carcinomas than in differentiated types (194). In colon cancer, Bauer et al. 
studied 355 primary resected colon carcinoma by IHC and found that high HSP70 expression 
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is associated with tumour grade, distant metastasis and poor clinical outcome in colon cancer 
(210). In bladder cancer, Syrigos et al. found that HSP70 overexpression correlated positively 
with the grade and stage of bladder carcinoma. Also, HSP-70 expression correlated closely 
with a poor outcome of 58 patients with bladder carcinoma. Furthermore, HSP70 
overexpression correlated with increased cell proliferation rate and malignancy (224). Alexious 
et al. reported a significant positive correlation between proliferation rate index and aggressive 
subtype of medulloblastomas (225).  
In contrast, there are some tumour types where a lower expression of HSP70 is observed 
compared with adjusted normal tissue and there is no correlation between HSP70 levels and 
survival. For example, in patients with renal cancer, Santarosa et al. (1997) reported that 
HSP70-1 upregulation was associated with a better prognosis, irrespective of stage and 
histological grade (226). Similarly, Ramp et al. (2007) showed that HSP70 expression was 
decreased from well (G1) to poorly differentiated renal cell carcinoma (227). In oesophageal 
squamous cell carcinoma, Nakajima et al. found that HSP70 expression is frequently reduced 
in 102 patients with oesophageal squamous cell carcinoma and reduction of HSP 70 expression 
was significantly correlated with poor prognosis (228). In chondrosarcoma, Trieb et al. 
investigated IHC expression of HSP72 in 37 chondrosarcoma sections and 10 chondroma 
sections, finding a decreased HSP72 expression in chondrosarcoma correlating with low 
differentiation (229).  
4.1.4 Expression of HSP90 
HSP90 expression was rather different to that of HSP27 and HSP70; there is less expression 
of HSP90 across all type of tumours. Furthermore, there was no relationship between HSP90 
expression and clinicopathological parameters and survival. 
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Our results are in agreement with previous studies suggesting a decreased expression of HSP90 
in some types of tumours. Wang et al. (2014) investigated HSP90 expression in 32 cases of 
myxofibrosarcoma and 29 myxoid liposarcomas (MLS) by IHC. Only 4 cases of 
myxofibrosarcoma showed scattered HSP90 positivity, while all cases of MLS showed positive 
staining for HSP90. No correlation was found between expression of HSP90 and tumour size 
or grade (230). Nabu et al. (1998) reported that high expression of HSP90 was significantly 
correlated with lower tumour grade and a favourable prognosis in 44 endometrial carcinoma 
patients (231). Zagouri et al. (2010) reported that there was a statistically significant decrease 
in HSP90 expression in infiltrative lobular carcinomas of the breast of 32 patients compared to 
the adjacent normal breast ducts and lobules tissue (232). 
On the other hand, there is a large body of evidence supporting that HSP 90 is over-expressed 
in many cancers and is associated with high grade and poor survival. HSP90 has been found 
elevated in medulloblastoma, and there was a significant positive correlation between the 
expression of HSP90 and poor survival (225). In breast cancer, significant increased expression 
of HSP90 has been found in ductal carcinomas and associated with the higher malignant 
phenotype and poor survival (232, 233). Furthermore, Lim et al. reported that HSP90 
expression showed a strong association with poor prognostic factors of hepatocellular 
carcinoma, vascular invasion and metastasis (234). Similar findings were observed in bladder 
cancer, where the HSP90 level was correlated with a high-grade tumour (235). 
In this study, HSP90 was expressed in very low levels across all types of soft tissue tumours 
and there was no association between its expression, prognosis and other clinical variables, 
which may indicate that HSP90 may only play a minor role in soft tissue tumours. 
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4.2 Data relating to sarcoma tumour behaviour 
In this study, attempts have been made to correlate the expression of different biomarkers with 
clinical outcome in soft tissue sarcomas. To date, most of the prognostic aspects of the 
behaviour of a particular patient’s tumour are related back to the likelihood data derived from 
pooling information from groups of tumours, and there is nothing that can be used to predict 
the behaviour of a patient-specific tumour. However, it is the biological behaviour of neoplastic 
cells within tumours that are responsible for the resultant clinical outcomes. 
STS are a rare heterogeneous group of uncommon malignancies of mesenchymal origin, and 
new improved prognostic biomarkers are required to identify patients at high-risk for 
metastasis. Several known prognostic factors influence survival and outcome in sarcomas, such 
as location, age of the patient, surgical margins, tumour size, tumour subtypes, tumour grade 
genetic factors, unplanned excision and metastasis. However, the relevant prognostic value of 
each of these factors continues to be highly controversial (236). 
The most important property influencing the clinical outcome of malignant tumours is their 
ability to invade and metastasise. Metastasis represents a significant clinical adverse predictor, 
since curative treatment is not usually achievable as conventional chemotherapy is limited in 
its effectiveness, with around 30% of all patients showing no improvement in their survival 
rates following treatment (237). Significantly, some tumours with the same lineage, 
histological diagnosis and grade do respond to chemotherapy, whilst other, apparently 
identical, tumours do not. Why this should be is unknown, but clearly demonstrates that the 
underlying susceptibility has therapeutic and prognostic implications. 
Tumour grade is the most predictive time-honoured factor of distant metastatic disease and 
most likely to influence a decision to initiate treatment with adjuvant therapy. Hence, the 
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grading process is important in its ability to indicate clinical behaviour and the type of 
therapeutic intervention (2). Histological grading of STS consists of a low, intermediate and 
high grade. The higher the grade, the stronger the correlation with the occurrence of metastases 
and shorter patient survival. An earlier study found that the metastatic potential of low-grade 
sarcomas is 5–10%, of intermediate-grade 25–30%, and of high-grade is approximately 50–
60% (32). Nonetheless, it is the impact of histological type which represents the principal 
confounding factor in grading, such that for some sarcomas, grade is less important than 
subtype in defining a behaviour such as synovial sarcoma (15). For others, the usual grading 
criteria are not applicable, for example, clear cell sarcoma tumour, which shows aggressive 
behaviour no matter what its histological appearance (2). The influence of tumour subtype has 
been considered an important factor that confounds grading systems in sarcomas. However, this 
may be related to other prognostic factors such as grade, in that some tumours such as synovial 
sarcoma are always high grade and others like well differentiated liposarcomas are invariably low 
grade (15). 
Another prognostic factor that has been found to influence survival and metastasis in STS is 
age. In this respect, two studies have reported a better outcome for patients younger than 40 
years compared to those older than 40 years at diagnosis (238, 239). Furthermore, tumour size 
is related to metastasis and survival in sarcomas; the smaller the tumour, the more likely it is 
to result in a universally good outcome. Geer et al. (1992) (240) provided support for the theory 
that in tumours of the extremities, small tumour size (< 5cm) carries a universally good 
prognosis, irrespective of grade, depth or location, and have found that surgical excision alone 
is usually sufficient to treat these tumours (240). Conversely, another study by Stojadinovic et 
al. (2002) shows that a large tumour size (> 10cm) has been consistently associated with a poor 
prognosis due to a high rate of metastatic recurrence (39). 
 
126 
It is widely held that by understanding the biology of cancer cells, it might be possible to 
individualise therapy and to produce much clearer and biologically more pertinent markers of 
tumour behaviour and potential response to specific treatments (154). In the current study, 
attempts have been initiated to identify such criteria in this poorly understood group of tumours 
by investigating potential interesting molecular biomarkers that have shown to have a pivotal 
role in tumorigenesis and aggressiveness in many types of cancer cell.  
As in all early studies of cancer biology and its relationship to cell and tumour behaviour, little 
is known about the role of HSPs in soft tissue sarcomas. In a proteomic study, Suehara et al. 
demonstrated that the expression of HSP27 was associated with histological grading and 
patient survival in Leiomyosarcoma (196). Furthermore, Bekki et al. published recently that 
HSP90 is highly expressed in undifferentiated pleomorphic sarcoma (UPS) and is considered 
as a poor prognostic factor (197). Data of relevance to understanding how biomarker 
expression should be analysed, that is, the need to take into account expression of what at first 
might appear to be key biomarkers in benign tumours, have also been identified.  
In this study, HSP expression was not significantly correlated with survival or metastatic 
disease, which might be due to the size of our sample or the follow-up interval. However, our 
data showed that high expression of HSP was associated with a clinical indicator of poor 
prognosis, the largest tumour diameter and the highest grade. This is the most significant 
clinical prognostic indicator for high risk of metastasis in STS (2). The biomarkers also showed 
differences in expression across the range of tumours. In general terms, some biomarker 
expression varied across the benign/malignant divide and others varied with the grade. In this 
discussion, variation across the benign/malignant divide is seen as evidence of an association 
with “malignant behaviour” (i.e. in some way the expression of the gene relates to the cellular 
changes associated with the development of a malignant phenotype). The expression of some 
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biomarkers not only varied across the benign/malignant divide, but also with the grade of the 
tumour. As increasing grade is, in general terms, associated with a poor outlook, these 
biomarkers are described as being associated with aggressiveness as well as the development 
of a malignant phenotype.  
In these analyses, the distinctions made must be seen within the context of tumour group size 
and data spread, and as such, cannot be taken as definitive but rather, in a study such as this, 
one of the first of its type in the field, as providing insight into the behaviour of sarcoma cells 
and whole tumours. The precise significance of these data is difficult to assess. Creating ratios 
of two sets of numbers generated as these have been, is open to criticism but they nevertheless, 
do stress potential and actual differences between different tumour types.  
4.3 Discussion on variation in expression of HSPs in tumours 
The reason for the discrepancy in the expression of different HSPs in various tumours in the 
literature is not very clear. The differences might be explained by heterogeneity of the tumour, 
differences in the stage of the disease, treatment modalities, immunohistochemical methods, 
case selection, and possible differences in embedding and processing techniques. However, the 
heterogeneity of expression of HSPs raises the question of what factor(s) might influence the 
differential expression of HSPs in different type and grade of the tumour. Indeed, could the 
higher expression of HSPs be related to tumour necrosis, proliferation or the presence of a 
specific type of molecule. In particular, it raises the question “if we could establish the 
signalling mechanism for HSPs production, could this be a therapeutic target”.  
HSP genes are activated at the transcriptional level by HSF1 and the capability of cells to react 
to stress by rising their HSP levels depends on the action of binding to the promoter regions of 
all HSP genes to activate their immediate and massive transcription (148, 186, 241). However, 
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the pathways of induction of HSPs in cancer are still under intense investigation, and no clear 
consensus has yet emerged. Such mechanisms may include transcription and translation of 
HSPs due to coupling of HSF1 expression to malignant cell signal transduction.  
Furthermore, research on gene expression in neoplasm has noted that the coupling between 
transcription and translation is often interrupted. A study of HSP gene expression in prostate 
carcinoma showed that HSP mRNA expression and protein expression altered considerably 
and that the levels of some HSPs were increased, while HSP mRNA levels were not notably 
changed (242). However, a popular rationale for HSP increases in cancer is the “addiction to 
chaperones” hypothesis. According to this hypothesis, HSP increases are fed in cancer through 
the proliferation of mutated proteins due to the “mutator phenotype” correlated with cancer, to 
increases in total levels of mRNA translation that accompany transformation and raised protein 
expression due to the polyploidy of many cancerous cells (243, 244). Therefore, addiction is 
caused by the demand for HSPs to chaperone the raised protein load that accompanies 
transformation and the instability of many mutant proteins. As elevated protein expression and 
gene mutation are thought to be key drivers of tumour progression, an increased supply of 
molecular chaperones is needed to sustain the addiction. This is an attractive hypothesis as it 
links the findings in oncology with what is speculated to be the driving reason for HSP 
induction during stress. Though this mechanism is difficult to test, there is significant indirect 
evidence to suggest its merit, coming from studies of HSP inhibitors in cancer and there is 
considerable evidence gained by examining inhibitors of HSP90 in vitro studies. For example, 
animal experiments and clinical trials have suggested that inhibiting HSP90 using small 
molecule inhibitors causes the depletion of a broad spectrum of oncogenes (presumably due to 
unfolding and proteolysis) and inhibition of tumour growth(183).  
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Finally, confronted with such complex systems of production, activation and regulation, the 
prospect of unravelling the involvement of HSPs in sarcoma behaviour and the outcome is 
daunting. A criticism of this study might be that it is not all inclusive, but faced with this level 
of complexity and a general paucity of previous literature about HSP expression in sarcomas, 
the approach adopted here has been to extrapolate from what is known, working within the 
limits of the available material. 
4.4 Limitations of this study 
This is a study based on the use of immunohistochemical identification of biomarker 
expression in archived formalin-fixed, wax-embedded tissue, resulting in several limitations. 
First, the sample size was small due to the difficulty in finding more samples to assess more 
types of sarcoma and the rarity of tumours arising from soft tissues. Furthermore, this study 
relied on only one block from each tumour, which was taken for research only. Therefore, the 
concern was always related to the constraints of using archived tissue biopsy. In addition, the 
current study was limited by the relatively small sample size of some subgroups, which may 
not have been sufficient to overcome the influences of the histological heterogeneity, thus 
limiting the conclusive power of the study. 
Due to the rarity of sarcomas, the present study focused on archived tissue to obtain sufficient 
material for the study. This material was formalin-fixed and paraffin embedded, with limited 
clinical and pathological data available. These constraints limited the techniques that could be 
employed to examine the expression of the chosen biomarkers to IHC and in situ hybridisation. 
IHC was chosen because by studying the expression of protein, one of the unknowns in 
investigating HSPs, translation of mRNA into protein, was eliminated.  
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Another concern is the limitations of IHC. IHC is a well-established, broadly accepted 
technique in both clinical and experimental medical research. However, IHC also has many 
limitations because it is a multi-step procedure and each step is vital. According to current IHC 
concepts, the challenges can be divided into three main variables, pre-analytical, analytical and 
post-analytical variables. Pre-analytical variables of IHC include any steps in obtaining the 
tissue sample, tissue processing, tissue fixation, and elements of tissue handling. Analytical 
variables include slide thickness, selection of antibody clones and their titration, determining 
the detection systems and antigen retrieval procedure. Finally, post-analytical variables of IHC 
include interpretation and reporting of the results. Despite all current recommendations, post-
analytical variables are the most frivolous part of many studies using IHC. Hence, the most 
important step of IHC is the final scoring system. Although there is no gold standard for HSP 
expression scoring system, both automated analytic systems and semi-quantitative scoring 
systems were used in this study to reduce the subjectivity of values scores and increase 
repeatability of scoring systems. However, our automated analytic method (ImageJ) did not 
consider cellularity of tumours which might lead to some calculation bias. Moreover, it is 
expensive and time-consuming, and for these reasons, it was not possible to test for more HSPs 
and, therefore, conduct more comprehensive research into HSPs in STS tumours.  
Another limitation is relating key molecules to one another. In the context of this study, HSPs 
are complexly activated and inhibited, so translating from IHC-expression into enzyme activity 
is impossible. However, there are real constraints on examining the activity of proteins in a 
very small area of tissue and IHC is the best way to address research questions that might then 
lead to the design of different and more appropriate experiments. The constraints of examining 
for HSP activity are related to production (whether all the proteins present in the cytoplasm are 
excreted), activation (some HSPs use other proteins, including HSPs to activate themselves) 
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and inhibition, hence, experiments were conducted to compare expression of the various 
molecules.  
A final limitation of this study is inadequate access to patient data and absence of 
comprehensive follow-up information. Without such data, survival analyses are not possible. 
In cancer studies with an extended follow-up, there are data on early and late recurrences as 
well as metastases. This study has not “closed the loop” in respect of the issue of assessing 
whether HSP expression might assist in patient management prospectively. As such, it would 
be of great importance to conduct follow-up studies to determine whether, for instance, levels 
of HSP expression can help to assign patients to different treatment strategies or to identify 
prognostic factors that may lead to the identification of novel targets for therapy.  
The limitations addressed above bring into focus the urgent need to improve the existing 
understanding of active biological processes and underlying mechanisms of disease 


















5 Conclusion & Future Work 
5.1 General Conclusions 
Soft tissue sarcomas have generally been studied less extensively than carcinomas, so the 
advances in biological understanding that have led to improved diagnosis and treatment of 
carcinomas have yet to be translated into soft tissue sarcoma. Although rare, they represent an 
important group of cancers, of which the biology is relatively unknown and therefore, they 
require further investigation. However, because of their rarity, obtaining these tumours to study 
is difficult and, hence, any work that can be done on archived tissue could be very important.  
This thesis examined the expression of HSP27, HSP70 and HSP90 in adult 
myofibroblastic/fibroblastic tumours of extremities using immunohistochemistry. The study 
showed differences in expression related to markers of behaviour and aggressiveness in these 
tumours that might form the basis of more focused investigations in the future.  
In conclusion, there was a statistically significant difference in HSP70 expression between 
myofibroblastic/fibroblastic sarcoma and non-metastasising tumours; HSP70 expression was 
higher in sarcoma than non-metastasising counterparts. Also, HSP70 was positively correlated 
with the grade of STSs, with elevated levels of HSP70 associated with a higher grade of STSs. 
Although HSP27 expression was higher in malignant than benign tumours, there was no 
statistically significant. Also, there was no significant positive correlation between HSP27 
expression and clinicopathological features of STSs. On the other hand, HSP90 expression is 
relatively low in all myofibroblastic/fibroblastic tumours compared to other studied HSPs. 
There was no statistically significant difference in HSP90 expression between sarcoma and 
non-metastasising tumours. Also, there was no correlation between HSP90 expression and 
 
134 
clinicopathological features of STSs. Finally, there was no significant relationship found 
between staining of any of the studied biomarkers and the age and sex of the patients.  
The findings of this study indicate that HSP70 and, to a lesser extent, HSP27 might have a role 
in sarcoma behaviour (as defined by the surrogates of tumour type and grade) and may provide 
prognostic information for clinicians in the future. Further studies evaluating HSPs in 
sarcomas, within the newly described model, may provide a new avenue of treatment for 
sarcoma patients.  
5.2 Future Work 
HSPs are well-established as having a complex and key role in tumour growth, invasion, 
metastasis, and tumour progression. The findings presented in this thesis have raised several 
questions in areas that would provide interesting topics for future investigations. The key 
purpose of further study should explain the invasion and haematogenous spread of sarcomas 
in order to understand why some patients survive and others die. The results of this study have 
raised many issues that could guide further work. Some issues reflect the limitations of the 
study and the material available. The main suggestions for future work consequent upon these 
are:  
➢ More sarcomas and their benign counterparts need to be tested. This study has shown 
that not all benign tumours express biomarkers in the same way and some behave in 
unexpected ways that affect how expression in malignant tumours should be 
interpreted.  
➢ Even though IHC is one of the best methods for examining protein expression in the 
core tissue of sarcomas, other technologies may need to be applied to the problem of 
mechanisms of invasion. The key to this would be taking the findings from this in vivo 
study and testing them in cell-based in vitro systems.  
➢ More comparisons will need to be made between gene expression and outcome (e.g. 
not just survival but perhaps also a response to drugs etc.).  
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➢ The key to overcoming some of these problems is the development of a dedicated soft 
tissue tumour bank, probably at the national level, of fresh and processed tissue and 
other samples (e.g. blood) from patients with these rare tumours to allow studies of 
sufficient size to be undertaken with statistical validity.  
Some areas of further study directly relate to the findings, some require expansion, some further 
investigation and others putting into the context of an increasing knowledge base, the most 
urgent being functional studies to establish the role of HSPs in the STS. The key message of 
this thesis, as derived from the data presented, is that the HSPs are expressed in human STS of 
extremities in both benign and malignant tumours, but their function, particularly the roles of 
HSPs, is not completely understood. Therefore, functional studies are required to establish the 
role of the HSPs in the STS. This raises many questions such as, does blocking the expression 
of HSPs increase or decrease the activation of some HSPs and other enzymes, including HSPs 
to activate themselves? or does increasing the expression of HSPs increase or decrease tumour 
progression? Moreover, further investigation into the regulation of HSPs in human soft tissue 
sarcoma of extremities is required; there is much more to learn about how HSPs are regulated 
in STS. The effects of HSP expression in human STS and the role of HSF as inducer facilitators 
of HSPs activity have not been examined in detail, therefore, investigating the effect of 
different HSPs and HSF expression in human STS of extremities will further the understanding 
of how the HSPs and HSFs are regulated in STS. 
These questions could be answered by investigations using more advanced methodologies than 
those possible in this study, such as the development of “knock-down” models of tumour cells 
for individual HSPs in a sequence-specific manner and thus, enable the function of each HSP 
to be investigated. Finally, the process of carcinogenesis involves a complex array of genetic 
and epigenetic alterations, which contribute to cancer pathogenesis (245), eventually resulting 
in a unique malignant tissue. This may alter the HSP context and behaviour dramatically, 
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therefore, it is important to determine whether changes in the expression of the HSPs at 

















Appendix A: LBIH Biobank Patient Consent Form 
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Appendix C: Immunohistochemistry Protocol - Using PT-Linker & 
DAKO Autostainer 
This protocol is adapted from Liverpool Ocular Oncology Research Group (LOORG) 
1. Turn on PT-Link and press “Run” to begin heating to 65°C (approx 20 minutes).  
2. Label slides with antibody, dilution and date, using a pencil. 
3. When 65°C is reached, place slides in staining rack. The PT Link will heat to 96°C, hold for 20 
minutes, and return to 65°C (approx 1 hour 10 minutes) 
4. Wash with Envision Flex-Wash buffer and place on DAKO. 
5. Add 100µl Envision-Flex block and incubate at room temperature (RT) for 5 minutes. 
6. Bring reagents required for staining run to room temperature and then programmed all required 
agents. 
7. Then, load the reagent vials according to the Reagent Layout Map, ensuring that enough reagent 
is in the vials to complete the programmed run. 
8. Dilute primary antibody to appropriate concentration using antibody diluent (Envision-Flex). 
Add 100µl primary antibody, cover and incubate at room temperature for 30 minutes. 
9. Add 100µl of appropriate linker (i.e. mouse for mouse primary antibody) and incubate at room 
temperature for 15 minutes. 
10. Add 100µl of HRP and incubate at room temperature for 20 minutes. 
11. Make up DAB (make fresh each time, using empty autostainer vial), 1 drop of DAB per 1ml of 
DAB substrate buffer. Add 100µl DAB solution to each slide then incubate at room temperature 
for 20 minutes. Place any waste DAB in the hazardous waste container attached to the 
autostainer then rinse tube well with a small volume of Milton. 
12. Dip in distilled water. 
13. Transfer slides to horse-shaped rack. 30 seconds - 1 minute in haematoxylin. This time will 
vary depending on your haematoxylin batch! 
14. Place rack into a bath of running tap water until the water runs clear. 
15. Dip in and immediately remove rack from the acid alcohol. 
16. Place rack back into the bath of running tap water until the slides are no longer pink. 
17. Dip in Scott’s tap water/ammonia water for 30 seconds. 
18. Place rack back into the bath of running tap water for 1 minute. 
19. Dehydrate through the ethanol series in the fume hood. This includes 5x IMS (Industrial 
Methylated Spirits) and 2x xylene. Agitate for 10 seconds at each stage, vigorously. 




Appendix D: Macro Code for Image J analysis 
//Image selection code 
title = getTitle(); // get the title of the current image 
imageOfInterest = title+"-(Colour_2)";  // the deconvolved imageName model 
//Colour[1]: 
  Red1=0.6500286; 
  Green1=0.704;031 
  Blue1=0.2860126; 
//Colour[2]: 
  Red2=0.26814753; 
  Green2=0.57031375; 
  Blue2=0.77642715; 
//Colour[3]: 
  Red3=0.7110272; 
  Green3=0.42318153; 
  Blue3=0.5615672; 
run("Colour Deconvolution", "vectors=[User values] show [r1]=Red1 [g1]=Green1 [b1]=Blue1 
[r2]=Red2 [g2]=Green2 [b2]=Blue2 [r3]=Red3 [g3]=Green3 [b3]=Blue3"); 
selectImage(imageOfInterest);  
// select the imageOf Interest 
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